FORM PTO-1390 (Modified) (REV 11-2000) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES · DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER	U.S APPLICATION NO. (IF KNOWN, SEE 37 CFR
29729/37581	09/889075

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/AU00/00011	11 January 2000	11 January 1999

TITLE OF INVENTION
CATALYTIC MOLECULES

APPLICANT(S) FOR DO/EO/US
DAVID G. ATKINS, ANDREW BAKER, LEVON M. KHACHIGIAN

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☐ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
   a. ☐ is attached hereto (required only if not communicated by the International Bureau).
   b. ☐ has been communicated by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. ☐ is attached hereto.
   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☐ Other items or information:

JC18 Rec'd PCT/PTO 11 JUL 2001

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER
09/889075	PCT/AU00/00011	29729/37581

24. The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

		CALCULATIONS PTO USE ONLY
☒ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	**$1000.00**	
☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	**$860.00**	
☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	**$710.00**	
☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	**$690.00**	
☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	**$100.00**	
ENTER APPROPRIATE BASIC FEE AMOUNT =		**$1,000.00**
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).		**$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	43 - 20 =	23	x $18.00	**$414.00**
Independent claims	1 - 3 =	0	x $80.00	**$0.00**
Multiple Dependent Claims **(check if applicable)**.			☒	**$270.00**
TOTAL OF ABOVE CALCULATIONS =				**$1,684.00**
☐ Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				**$0.00**
SUBTOTAL =				**$1,684.00**
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +				**$0.00**
TOTAL NATIONAL FEE =				**$1,684.00**
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).** ☐				**$0.00**
TOTAL FEES ENCLOSED =				**$1,684.00**
				Amount to be: refunded $
				charged $

a. ☒ A check in the amount of **$1,684.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **13-2855** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

WILLIAMS, Joseph A. Jr.
MARSHALL, O'TOOLE, GERSTEIN MURRAY & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

Joseph A. Williams, Jr.
SIGNATURE

Joseph A. Williams, Jr.
NAME

38,659
REGISTRATION NUMBER

11 July 2001
DATE

PATENT
30397/37581

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Atkins et al.**

Serial No.: 09/889,075
U.S. National Phase of PCT/AU00/00011

Filed: **January 11, 2000**

For: Catalytic Molecules

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:

September 4, 2002

David A. Gass
Registration No. 38,153
Attorney for Applicants

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Please amend the above-identified application as follows, prior to calculation of the filing fee (with extra claims) and prior to examination of the merits:

IN THE CLAIMS:

AMEND Claims 48, 49 and 59as follows:

48. (AMENDED) A pharmaceutical composition comprising a DNAzyme according to claim 20 and a pharmaceutically acceptable carrier.

49. (AMENDED) A method of inhibiting EGR-1 activity in cells which comprises exposing the cell to a DNAzyme according to claim 20.

59. (AMENDED) An angioplastic stent for inhibition of the onset of restenosis, which comprises an angioplastic stent operably coated with a prophylactially effective dose of DNAzyme according to claim 20.

REMARKS

The applicant respectfully submits that all claims are now of proper form and scope for allowance. Early and favorable consideration is respectfully requested.

The foregoing amendments are intended solely to reduce the PTO fees for multiple dependent claims and claims in excess of 20. The applicants reserve the right to pursue subject matter of any cancelled claim in this application or any related (*e.g.*, continuing) application.

Attached hereto is a marked-up version of the changes made to the claims by the foregoing amendments. The attached page is captioned **"Version with markings to show changes made."**

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By: 

David A. Gass
Reg. No. 38,153
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

September 3, 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

AMEND Claims 48, 49 and 59 as follows:

48. (AMENDED) A pharmaceutical composition comprising a DNAzyme according to [any one of claims 20 to 47] claim 20 and a pharmaceutically acceptable carrier.

49. (AMENDED) A method of inhibiting EGR-1 activity in cells which comprises exposing the cell to a DNAzyme according to [any one of claims 20 to 47] claim 20.

59. (AMENDED) An angioplastic stent for inhibition of the onset of restenosis, which comprises an angioplastic stent operably coated with a prophylactially effective dose of DNAzyme according to [any one of claims 20 to 47] claim 20.

PATENT
29729/37581

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: David G. Atkins et al)
)
U.S. National Phase of)
International Application No:)
PCT/AU/00/00011)
filed January 11, 2000)
)
Serial No: Not yet assigned)
)
Filed: herewith)
)
Title: CATALYTIC MOLECULES)
)
Group Art Unit: Not yet assigned)
)
Examiner: Not yet assigned)

"EXPRESS MAIL" mailing label No. EL564462123US

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Box PCT, Commissioner for Patents, Washington, D.C. 20231, on this date

July 11, 2001

Richard Zimmermann

PRELIMINARY AMENDMENT

Box PCT
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This amendment is being filed with the U.S. National filing of the above identified PCT application. The Applicant requests entry of this amendments prior to calculation of the filing fee and prior to examination on the merits.

AMENDMENTS

In the Abstract:

Please add to the application the abstract attached hereto.

In the claims:

Please cancel claims 1-19 and insert the following claims 20-62 as shown below:

20. A DNAzyme which specifically cleaves EGR-1 mRNA, the DNAzyme comprising
(i) a catalytic domain which cleaves mRNA at a purine:pyrimidine cleavage site;
(ii) a first binding domain continuous with the 5' end of the catalytic domain; and
(iii) a second binding domain continuous with the 3' end of the catalytic domain,
wherein the binding domains are sufficiently complementary to the two regions immediately flanking a purine:pyrimidine cleavage site within the region of EGR-1 mRNA corresponding to nucleotides 168-332 as shown in SEQ ID No: 1, such that the DNAzyme cleaves the EGR-1 mRNA.

21. A DNAzyme as claimed in claim 20 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

22. A DNAzyme as claimed in claim 20 in which the cleavage site is selected from the group consisting of
(i) the GU site corresponding to nucleotides 198-199;
(ii) the GU site corresponding to nucleotides 200-201;
(iii) the GU site corresponding to nucleotides 264-265;
(iv) the AU site corresponding to nucleotides 271-272;
(v) the AU site corresponding to nucleotides 301-302;
(vi) the GU site corresponding to nucleotides 303-304; and
(vii) the AU site corresponding to nucleotides 316-317.

23. A DNAzyme as claimed in claim 22 in which the cleavage site is the AU site corresponding to nucleotides 271-272.

24. A DNAzyme as claimed in claim 22 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

25. A DNAzyme as claimed in claim 23 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

26. A DNAzyme as claimed in claim 20 in which the catalytic domain has the nucleotide sequence GGCTAGCTACAACGA [SEQ. ID. NO: 2].

27. A DNAzyme as claimed in claim 26 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

28. A DNAzyme as claimed in claim 26 in which the cleavage site is selected from the group consisting of

(i) the GU site corresponding to nucleotides 198-199;
(ii) the GU site corresponding to nucleotides 200-201;
(iii) the GU site corresponding to nucleotides 264-265;
(iv) the AU site corresponding to nucleotides 271-272;
(v) the AU site corresponding to nucleotides 301-302;
(vi) the GU site corresponding to nucleotides 303-304; and
(vii) the AU site corresponding to nucleotides 316-317.

29. A DNAzyme as claimed in claim 28 in which the cleavage site is the AU site corresponding to nucleotides 271-272.

30. A DNAzyme as claimed in claim 28 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

31. A DNAzyme as claimed in claim 29 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

32. A DNAzyme as claimed in claim 20 wherein each binding domain is nine or more nucleotides in length.

33. A DNAzyme as claimed in claim 32 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

34. A DNAzyme as claimed in claim 32 in which the cleavage site is selected from the group consisting of

(i) the GU site corresponding to nucleotides 198-199;
(ii) the GU site corresponding to nucleotides 200-201;
(iii) the GU site corresponding to nucleotides 264-265;
(iv) the AU site corresponding to nucleotides 271-272;
(v) the AU site corresponding to nucleotides 301-302;
(vi) the GU site corresponding to nucleotides 303-304; and
(vii) the AU site corresponding to nucleotides 316-317.

35. A DNAzyme as claimed in claim 34 in which the cleavage site is the AU site corresponding to nucleotides 271-272.

36. A DNAzyme as claimed in claim 34 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

37. A DNAzyme as claimed in claim 35 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

38. A DNAzyme as claimed in claim 32 in which the catalytic domain has the nucleotide sequence GGCTAGCTACAACGA [SEQ ID NO: 2].

39. A DNAzyme as claimed in claim 38 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

40. A DNAzyme as claimed in claim 38 in which the cleavage site is selected from the group consisting of

(i) the GU site corresponding to nucleotides 198-199;
(ii) the GU site corresponding to nucleotides 200-201;
(iii) the GU site corresponding to nucleotides 264-265;
(iv) the AU site corresponding to nucleotides 271-272;
(v) the AU site corresponding to nucleotides 301-302;
(vi) the GU site corresponding to nucleotides 303-304; and
(vii) the AU site corresponding to nucleotides 316-317.

41. A DNAzyme as claimed in claim 40 in which the cleavage site is the AU site corresponding to nucleotides 271-272.

42. A DNAzyme as claimed in claim 40 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

43. A DNAzyme as claimed in claim 41 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

44. A DNAzyme as claimed in claim 20 which has a sequence selected from the group consisting of:

(i) 5'-caggggacaGGCTAGCTACAACGAcgttgcggg (SEQ ID NO: 3);
(ii) 5'-tgcaggggaGGCTAGCTACAACGAaccgttgcg (SEQ ID NO: 4);
(iii) 5'-catcctggaGGCTAGCTACAACGAgagcaggct (SEQ ID NO: 5);
(iv) 5'-ccgcggccaGGCTAGCTACAACGAcctggacga (SEQ ID NO: 6);
(v) 5'-ccgctgccaGGCTAGCTACAACGAcccggacgt (SEQ ID NO: 7);
(vi) 5'-gcggggacaGGCTAGCTACAACGAcagctgcat (SEQ ID NO: 8);
(vii) 5'-cagcggggaGGCTAGCTACAACGAatcagctgc (SEQ ID NO: 9); and
(viii) 5'-ggtcagagaGGCTAGCTACAACGActgcagcgg (SEQ ID NO: 10).

45. A DNAzyme as claimed in claim 44 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

46. A DNAzyme as claimed in claim 44 which has the sequence: 5'-ccgcggccaGGCTAGCTACAACGAcctggacga (SEQ ID NO: 6).

47. A DNAzyme as claimed in claim 46 wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3'-end of the catalytic domain.

48. A pharmaceutical composition comprising a DNAzyme according to any one of claims 20 to 47 and a pharmaceutically acceptable carrier.

49. A method of inhibiting EGR-1 activity in cells which comprises exposing the cell to a DNAzyme according to any one of claims 20 to 47.

50. A method as claimed in claim 49 wherein the cells are vascular cells.

51. A method as claimed in any one of claims 49 wherein the cells are cells involved in neoplasia.

52. A method of inhibiting proliferation or migration of cells in a subject which comprises administering to the subject a prophylactically effective dose of the pharmaceutical composition according to claim 48.

53. A method as claimed in claim 52 wherein the cells are vascular cells.

54. A method as claimed in any one of claims 52 wherein the cells are cells involved in neoplasia.

55. A method of treating a condition associated with cell proliferation or migration in a subject which comprises administering to the subject a therapeutically effective dose of the pharmaceutical composition according to claim 48.

56. A method as claimed in claim 55 wherein the cells are vascular cells.

57. A method as claimed in any one of claims 55 wherein the cells are cells involved in neoplasia.

58. A method as claimed in claim 55 wherein the condition associated with cell proliferation or migration is selected from the group consisting of post-angioplasty restenosis, vein graft failure, hypertension, transplant coronary disease, and complications associated with atherosclerosis or peripheral vascular disease.

59. An angioplastic stent for inhibition of the onset of restenosis, which comprises an angioplastic stent operably coated with a prophylactically effective dose of a DNAzyme according to any one of claims 20 to 47.

60. A method for inhibiting the onset of restenosis in a subject undergoing angioplasty, which comprises topically administering a prophylactically effective dose of a pharmaceutical composition according to claim 48 to the subject at around the time of the angioplasty.

61. A method according to claim 60 in which the pharmaceutical composition is administered by catheter.

62. A method for inhibiting the onset of restenosis in a subject undergoing angioplasty, which comprises topically administering a stent according to claim 58 to the subject at around the time of the angioplasty.

REMARKS

The Applicant is canceling the original claim set without prejudice to the Applicant's right to pursue claims of the same or similar scope in a duly filed continuing application, and is filing a new set of claims intended solely to place the claims in proper multiple dependent format. The following table demonstrates the new claims as they correspond to the original claims set:

New Claim No.	Original Claim No. and (Dependency)
Claim 20	Claim 1
Claim 21	Claim 8 (1)
Claim 22	Claim 4 (1)
Claim 23	Claim 5 (4)
Claim 24	Claim 8 (4)
Claim 25	Claim 8 (5)
Claim 26	Claim 3 (1)
Claim 27	Claim 8 (3)
Claim 28	Claim 4 (3)
Claim 29	Claim 5 (4)
Claim 30	Claim 8 (4)
Claim 31	Claim 8 (5)
Claim 32	Claim 2 (1)
Claim 33	Claim 8 (2)
Claim 34	Claim 4 (2)
Claim 35	Claim 5 (4)
Claim 36	Claim 8 (4)
Claim 37	Claim 8 (5)
Claim 38	Claim 3 (2)
Claim 39	Claim 8 (3)
Claim 40	Claim 4 (3)
Claim 41	Claim 5 (4)
Claim 42	Claim 8 (4)
Claim 43	Claim 8 (5)
Claim 44	Claim 6 (1)
Claim 45	Claim 8 (6)
Claim 46	Claim 7 (6)
Claim 47	Claim 8 (7)
Claim 48	Claim 9 (1-8)

New Claim No.	Original Claim No. and (Dependency)
Claim 49	Claim 10 (1-8)
Claim 50	Claim 13 (10)
Claim 51	Claim 14 (10)
Claim 52	Claim 11 (9)
Claim 53	Claim 13 (11)
Claim 54	Claim 14 (11)
Claim 55	Claim 12 (9)
Claim 56	Claim 13 (12)
Claim 57	Claim 14 (12)
Claim 58	Claim 15 (12)
Claim 59	Claim 16 (1-8)
Claim 60	Claim 17 (9)
Claim 61	Claim 18 (17)
Claim 62	Claim 19 (15)

The new claim set does not introduce new matter.

The abstract of the disclosure is identical to the abstract in the published PCT pamphlet.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606

By: _____
Joseph A. Williams, Jr. (Reg. No. 38,659)
Attorney for Applicants

Dated: July 11, 2001

CATALYTIC MOLECULES

FIELD OF THE INVENTION

The present invention relates to DNAzymes which are targeted against mRNA molecules encoding EGR-1 (also known as Egr-1 or NGFI-A). The present invention also relates to compositions including these DNAzymes and to methods of treatment involving administration of the DNAzymes.

BACKGROUND OF THE INVENTION

Egr-1 expression in Smooth Muscle Cells

Smooth muscle cells (SMCs) are well recognized as a significant cellular component of atherosclerotic and post-angioplasty restenotic lesions (Stary et al, 1995; Holmes et al, 1984). SMC migration and proliferation are key events in the pathogenesis of these vascular disorders (Jackson & Schwartz, 1992; Libby et al, 1995). The promoter regions of many genes that encode mitogenic and migratory factors expressed by SMCs in these lesions (Evanko et al, 1998; Murry et al, 1996; Ueda et al, 1996; Tanizawa et al, 1996; Rekhter & Gordon, 1994; Hughes et al, 1993; Brogi et al, 1993; Wilcox et al 1989; Wilcox et al, 1988) contain nucleotide (nt) recognition elements for the nuclear protein and transcription factor, Egr-1 (Khachigian & Collins, 1997; Khachigian et al, 1996). Egr-1 is not expressed in the unmanipulated artery wall, but is rapidly activated by mechanical injury (Khachigian et al, 1996; Silverman et al, 1997; Kim et al, 1995). It is also induced in vascular endothelial cells and/or SMCs exposed to fluid biomechanical forces (Khachigian et al, 1997; Sumpio et al, 1998) and multiple other pathophysiologically-relevant agonists (Delbridge & Khachigian, 1997).

DNAzymes

In human gene therapy, antisense nucleic acid technology has been one of the major tools of choice to inactivate genes whose expression causes disease and is thus undesirable. The anti-sense approach employs a nucleic acid molecule that is complementary to, and thereby hybridizes with, an mRNA molecule encoding an undesirable gene. Such hybridization leads to the inhibition of gene expression.

Anti-sense technology suffers from certain drawbacks. Anti-sense hybridization results in the formation of a DNA/target mRNA heteroduplex. This heteroduplex serves as a substrate for RNAse H-mediated degradation of the target mRNA component. Here, the DNA anti-sense molecule serves in a passive manner, in that it merely facilitates the required cleavage by endogenous RNAse H enzyme. This dependence on RNAse H confers limitations on the design of anti-sense molecules regarding their chemistry and ability to form stable heteroduplexes with their target mRNA's. Anti-sense DNA molecules also suffer from problems associated with non-specific activity and, at higher concentrations, even toxicity.

As an alternative to anti-sense molecules, catalytic nucleic acid molecules have shown promise as therapeutic agents for suppressing gene expression, and are widely discussed in the literature (Haseloff (1988); Breaker (1994); Koizumi (1989); Otsuka; Kashani-Sabet (1992); Raillard (1996); and Carmi (1996)). Thus, unlike a conventional anti-sense molecule, a catalytic nucleic acid molecule functions by actually cleaving its target mRNA molecule instead of merely binding to it. Catalytic nucleic acid molecules can only cleave a target nucleic acid sequence if that target sequence meets certain minimum requirements. The target sequence must be complementary to the hybridizing regions of the catalytic nucleic acid, and the target must contain a specific sequence at the site of cleavage.

Catalytic RNA molecules ("ribozymes") are well documented (Haseloff (1988); Symonds (1992); and Sun (1997)), and have been shown to be capable of cleaving both RNA (Haseloff (1988)) and DNA (Raillard (1996)) molecules. Indeed, the development of in vitro selection and evolution techniques has made it possible to obtain novel ribozymes against a known substrate, using either random variants of a known ribozyme or random-sequence RNA as a starting point (Pan (1992); Tsang (1994); and Breaker (1994)).

Ribozymes, however, are highly susceptible to enzymatic hydrolysis within the cells where they are intended to perform their function. This in turn limits their pharmaceutical applications.

Recently, a new class of catalytic molecules called "DNAzymes" was created (Breaker and Joyce (1995); Santoro (1997)). DNAzymes are single-stranded, and cleave both RNA (Breaker (1994); Santoro (1997)) and DNA (Carmi (1996)). A general model for the DNAzyme has been proposed, and is known as the "10-23" model. DNAzymes following the "10-23" model, also

referred to simply as "10-23 DNAzymes", have a catalytic domain of 15 deoxyribonucleotides, flanked by two substrate-recognition domains of seven to nine deoxyribonucleotides each. In vitro analyses show that this type of DNAzyme can effectively cleave its substrate RNA at purine:pyrimidine junctions under physiological conditions (Santoro (1997)).

DNAzymes show promise as therapeutic agents. However, DNAzyme success against a disease caused by the presence of a known mRNA molecule is not predictable. This unpredictability is due, in part, to two factors. First, certain mRNA secondary structures can impede a DNAzyme's ability to bind to and cleave its target mRNA. Second, the uptake of a DNAzyme by cells expressing the target mRNA may not be efficient enough to permit therapeutically meaningful results. For these reasons, merely knowing of a disease and its causative target mRNA sequence does not alone allow one to reasonably predict the therapeutic success of a DNAzyme against that target mRNA, absent an inventive step.

SUMMARY OF THE INVENTION

Accordingly, in a first aspect the present invention provides a DNAzyme which specifically cleaves EGR-1 mRNA, the DNAzyme including

(i) a catalytic domain which cleaves mRNA at a purine:pyrimidine cleavage site;

(ii) a first binding domain contiguous with the 5' end of the catalytic domain; and

(iii) a second binding domain contiguous with the 3' end of the catalytic domain,

wherein the binding domains are sufficiently complementary to two regions immediately flanking a purine:pyrimidine cleavage site within the region of EGR-1 mRNA corresponding to nucleotides 168 to 332 as shown in SEQ ID NO:1, such that the DNAzyme cleaves the EGR-1 mRNA.

In a second aspect the present invention provides a pharmaceutical composition including a DNAzyme according to the first aspect and a pharmaceutically acceptable carrier.

In a third aspect the present invention provides a method of inhibiting EGR-1 activity in cells which includes exposing the cells to a DNAzyme according to the first aspect of the present invention.

In a fourth aspect the present invention provides a method of inhibiting proliferation or migration of cells in a subject which includes administering to the subject a prophylactically effective dose of a DNAzyme according to the first aspect of the present invention.

In a fifth aspect the present invention provides a method of treating a condition associated with cell proliferation or migration in a subject which includes administering to the subject a prophylactically effective dose of a DNAzyme according to the first aspect of the present invention.

In a sixth aspect the present invention provides an angioplastic stent for inhibiting the onset of restenosis, which comprises an angioplastic stent operably coated with a prophylactically effective dose of a DNAzyme according to the first aspect.

In a seventh aspect, the present invention provides a method for inhibiting the onset of restenosis in a subject undergoing angioplasty, which comprises topically administering a stent according to the fifth aspect to the subject at around the time of the angioplasty.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 Sequence of NGFI-A DNAzyme (ED5), its scrambled control (ED5SCR) and 23 nt synthetic rat substrate. The translational start site is underlined.

Figure 2 NGFI-A DNAzyme inhibits the induction of NGFI-A mRNA and protein by serum. Northern blot analysis was performed with 25 μg of total RNA. The blot was stripped and reprobed for β-Actin. Autoradiograms were analyzed by scanning densitometry and the ordinate axis is expressed as NGFI-A band intensity as a fraction of β-Actin band intensity. The mean and standard errors of the mean are indicated in the figure. Data is representative of 2 independent experiments. * indicates $P<0.05$ (Student's paired t-test) as compared to control (FBS alone).

Figure 3 SMC proliferation is inhibited by NGFI-A DNAzyme. **a**, Assessment of total cell numbers by Coulter counter. Growth-arrested SMCs that had been exposed to serum and/or DNAzyme for 3 days were trypsinized followed by quantitation of the suspension. The sequence of AS2 is 5'-CTT GGC CGC TGC CAT-3' (SEQ ID NO: 20). **b**, Proportion of cells incorporating Trypan Blue after exposure to serum and/or DNAzyme. Cells were stained incubated in 0.2% (w:v) Trypan Blue at 22 °C for 5 min prior to quantitation by hemocytometer in a blind manner. **c**, Effect of ED5 on pup SMC proliferation. Growth-arrested WKY12-22 cells exposed to serum and/or DNAzyme for 3 days were resuspended and numbers were quantitated by Coulter counter. Data is representative of 2 independent experiments performed in triplicate. The mean and standard errors of the mean are indicated in the figure. * indicates $P<0.05$ (Student's paired t-test) as compared to control (FBS alone).

Figure 4 NGFI-A DNAzyme inhibition of neointima formation in the rat carotid artery. Neointimal and medial areas of 5 consecutive sections per rat (5 rats per group) taken at 250 μm intervals from the point of ligation were determined digitally and expressed as a ratio per group. The mean and standard errors of the mean are indicated by the ordinate axis. * denotes

$P<0.05$ as compared to the Lig, Lig+Veh or Lig+Veh+ED5SCR groups using the Wilcoxen rank sum test for unpaired data. Lig denotes ligation, Veh denotes vehicle.

Figure 5 Selective inhibition of human smooth muscle cell proliferation by DzA.

Figure 6 Specific inhibition of porcine retinal smooth muscle cell proliferation by DzA.

DETAILED DESCRIPTION OF THE INVENTION

Egr-1 (also known as NGFI-A and EGR-1) binds to the promoters of genes whose products influence cell movement and replication in the artery wall. Table 1 shows an alignment of the human EGR-1 cDNA sequence with the equivalent mouse (Egr-1) and rat (NGFI-A) sequences. The present inventors have now developed DNA-based enzymes that cut NGFI-A/Egr-1/EGR-1 RNA with high efficiency and specificity. The NGFI-A "DNAzyme" cleaved synthetic and *in vitro* transcribed NGFI-A RNA in a sequence-specific manner and inhibited production of NGFI-A in vascular smooth muscle cells without influencing levels of the related zinc finger protein, Sp1, or the immediate-early gene product, c-Fos. The DNAzyme blocked serum-inducible DNA synthesis in smooth muscle cells and attenuated total cell proliferation. The DNAzyme also inhibited the reparative response to mechanical injury, both in culture and in the rat carotid artery wall. These results indicate a necessary and sufficient role for NGFI-A/Egr-1/EGR-1 in vascular smooth muscle cell growth and provide the first demonstration of a DNAzyme targeted against NGFI-A/Egr-1/EGR-1 transcripts.

Accordingly, in a first aspect the present invention provides a DNAzyme which specifically cleaves EGR-1 mRNA, the DNAzyme including

(i) a catalytic domain which cleaves mRNA at a purine:pyrimidine cleavage site;

(ii) a first binding domain contiguous with the 5' end of the catalytic domain; and

(iii) a second binding domain contiguous with the 3' end of the catalytic domain,

wherein the binding domains are sufficiently complementary to two regions immediately flanking a purine:pyrimidine cleavage site within the region of EGR-1 mRNA corresponding to nucleotides 168 to 332 as shown in SEQ ID NO:1, such that the DNAzyme cleaves the EGR-1 mRNA.

As used herein, "DNAzyme" means a DNA molecule that specifically recognizes and cleaves a distinct target nucleic acid sequence, which may be either DNA or RNA

In a preferred embodiment of the first aspect of the present invention, the binding domains are complementary to the regions immediately flanking the cleavage site. It will be appreciated by those skilled in the art, however,

that strict complementarity may not be required for the DNAzyme to bind to and cleave the EGR-1 mRNA.

The catalytic domain of a DNAzyme of the present invention may be any suitable catalytic domain. Examples of suitable catalytic domains are described in *Santoro and Joyce, 1997* and US 5807718, the entire contents of which are incorporated herein by reference. In a preferred embodiment, the catalytic domain has the nucleotide sequence GGCTAGCTACAACGA (SEQ ID NO: 2).

Within the parameters of the present invention, the binding domain lengths (also referred to herein as "arm lengths") can be of any permutation, and can be the same or different. In a preferred embodiment, the binding domain lengths are at least 6 nucleotides. Preferably, both binding domains have a combined total length of at least 14 nucleotides. Various permutations in the length of the two binding domains, such as 7+7, 8+8 and 9+9, are envisioned. It is well established that the greater the binding domain length, the more tightly it will bind to its complementary mRNA sequence. Accordingly, in a more preferred embodiment, each domain is nine or more nucleotides in length.

Within the context of the present invention, preferred cleavage sites within the region of EGR-1 mRNA corresponding to nucleotides 168 to 332 are as follows:

(i) the GU site corresponding to nucleotides 198-199;
(ii) the GU site corresponding to nucleotides 200-201;
(iii) the GU site corresponding to nucleotides 264-265;
(iv) the AU site corresponding to nucleotides 271-272;
(v) the AU site corresponding to nucleotides 301-302;
(vi) the GU site corresponding to nucleotides 303-304; and
(vii) the AU site corresponding to nucleotides 316-317.

In a further preferred embodiment, the DNAzyme has a sequence selected from:

(i) 5'-caggggacaGGCTAGCTACAACGAcgttgcggg (SEQ ID NO: 3)
targets GU (nt 198, 199); arms hybridise to bp 189-207

(ii) 5'-tgcaggggaGGCTAGCTACAACGAaccgttgcg (SEQ ID NO: 4)
targets GU (nt 200, 201); arms hybridise to bp 191-209

(iii) 5'-catcctggaGGCTAGCTACAACGAgagcaggct (SEQ ID NO: 5)
targets GU (nt 264, 265); arms hybridise to bp 255-273

(iv) 5'-ccgcggccaGGCTAGCTACAACGAcctggacga (SEQ ID NO: 6)
targets AU (nt 271, 272); arms hybridise to bp 262-280

(v) 5'-ccgctgccaGGCTAGCTACAACGAcccggacgt (SEQ ID NO: 7)
targets AU (nt 271, 272); arms hybridise to bp 262-280

(vi) 5'-gcgggacaGGCTAGCTACAACGAcagctgcat (SEQ ID NO: 8)
targets AU (nt 301, 302); arms hybridise to bp 292-310

(vii) 5'-cagcgggaGGCTAGCTACAACGAatcagctgc (SEQ ID NO: 9)
targets GU (nt 303, 304); arms hybridise to bp 294-312

(viii) 5'-ggtcagagaGGCTAGCTACAACGActgcagcgg (SEQ ID NO: 10)
targets AU (nt 316, 317); arms hybridise to bp 307-325.

In a particularly preferred embodiment, the DNAzyme targets the AU site corresponding to nucleotides 271-272 (ie. the translation start codon).

In a further preferred embodiment, the DNAzyme has the sequence: 5'-ccgcggccaGGCTAGCTACAACGAcctggacga (SEQ ID NO: 6).

In applying DNAzyme-based treatments, it is preferable that the DNAzymes be as stable as possible against degradation in the intra-cellular milieu. One means of accomplishing this is by incorporating a 3'-3' inversion at one or more termini of the DNAzyme. More specifically, a 3'-3' inversion (also referred to herein simply as an "inversion") means the covalent phosphate bonding between the 3' carbons of the terminal nucleotide and its adjacent nucleotide. This type of bonding is opposed to the normal phosphate bonding between the 3' and 5' carbons of adjacent nucleotides, hence the term "inversion". Accordingly, in a preferred embodiment, the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3' end of the catalytic domain. In addition to inversions, the instant DNAzymes may contain modified nucleotides. Modified nucleotides

include, for example, N3'-P5' phosphoramidate linkages, and peptide-nucleic acid linkages. These are well known in the art.

In a particularly preferred embodiment, the DNAzyme includes an inverted T at the 3' position.

As will be appreciated by those skilled in the art, given that DNAzymes of the present invention cleave human EGR-1, similar DNAzymes can be produced to cleave the corresponding mRNA in other species, eg. rat (NGFI-A), mouse (Egr-1) etc. In a further aspect, the present invention provides such DNAzymes.

In a second aspect the present invention provides a pharmaceutical composition including a DNAzyme according to the first aspect and a pharmaceutically acceptable carrier.

In a third aspect the present invention provides a method of inhibiting EGR-1 activity in cells which includes exposing the cells to a DNAzyme according to the first aspect of the present invention.

In a fourth aspect the present invention provides a method of inhibiting proliferation or migration of cells in a subject which includes administering to the subject a prophylactically effective dose of a DNAzyme according to the first aspect of the present invention.

In a fifth aspect the present invention provides a method of treating a condition associated with cell proliferation or migration in a subject which includes administering to the subject a prophylactically effective dose of a DNAzyme according to the first aspect of the present invention.

In preferred embodiments of the third, fourth and fifth aspects of the present invention, the cells are vascular cells, particularly smooth muscle or endothelial cells. The cells may, however, be cells involved in neoplasia, such as tumour cells and the like.

Although the subject may be any animal or human, it is preferred that the subject is a human.

In a preferred embodiment, conditions associated with SMC proliferation(and migration) are selected from post-angioplasty restenosis, vein graft failure, transplant coronary disease and complications associated with atherosclerosis (cerebrovascular infarction (stroke), myocardial infarction (heart attack), hypertension or peripheral vascular disease (gangrene of the extremities).

Within the parameters of the fourth and fifth aspects of the present invention, any suitable mode of administration may be used to administer or deliver the DNAzyme.

In particular, delivery of the nucleic acid agents described may be achieved by one or more of the following methods:

(a) Liposomes and liposome-protein conjugates and mixtures.

(b) Using catheters to deliver intra-luminal formulations of the nucleic acid as a solution or in a complex with a liposome.

(c) Catheter delivery to adventitial tissue as a solution or in a complex with a liposome.

(d) Within a polymer formulation such as polyethylenimine (PEI) or pluronic gels or within ethylene vinyl acetate copolymer (EVAc). The polymer is preferably delivered intra-luminally.

(e) The nucleic acid may be bound to a delivery agent such as a targetting moiety, or any suitable carrier such as a peptide or fatty acid molecule.

(f) Within a viral-liposome complex, such as Sendai virus.

(g) The nucleic acid may be delivered by a double angioplasty balloon device fixed to catheter.

(h) The nucleic acid could be delivered on a specially prepared stent of the Schatz-Palmaz or derivative type. The stent could be coated with a polymer or agent impregnated with nucleic acid that allows controlled release of the molecules at the vessel wall.

In a preferred embodiment, the mode of administration is topical administration. Topical administration may be effected or performed using any of the various methods and delivery systems known to those skilled in the art. The topical administration can be performed, for example, via catheter and topical injection, and via coated stent as discussed below.

Pharmaceutical carriers for topical administration are well known in the art, as are methods for combining same with active agents to be delivered. The following delivery systems, which employ a number of routinely used carriers, are only representative of the many embodiments envisioned for administering the instant composition.

Topical delivery systems include, for example, gels and solutions, and can contain excipients such as solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic

polymers (e.g., polycarbophil and polyvinylpyrolidone). In the preferred embodiment, the pharmaceutically acceptable carrier is a liposome or a biodegradable polymer. Examples of agents which can be used in this invention include the following: (1) CellFectin, 1:1.5 (M/M) liposome formulation of the cationic lipid N,N^{I},N^{II},N^{III}-tetramethyl-N,N^{I},N^{II},N^{III}-tetrapalmitylspermine and dioleoyl phosphatidyl-ethanolamine (DOPE) (GIBCO BRL); (2) Cytofection GSV, 2:1 (M/M) liposome formulation of a cationic lipid and DOPE (Glen Research); (3) DOTAP (N-[1-(2,3-dioleoyloxy)-N,N,N-trimethyl-ammoniummethylsulfate) (Boehringer Mannheim); (4) Lipofectamine, 3:1 (M/M) liposome formulation of the polycationic lipid DOSPA and the neutral lipid DOPE (GIBCO BRL); (5) FuGENE^{6} (Roche Molecular Biochemicals); (6) Superfect (Qiagen); and (7) Lipofectamine 2000 (Gibco-life Technologies).

Examples of suitable methods for topical administration of the DNAzymes of the present invention are described in Autieri et al. (1995), Simons et al. (1992), Morishita et al. (1993), Bennett and Schwartz (1995) and Frimerman et al. (1999).

Determining the prophylactically effective dose of the instant pharmaceutical composition can be done based on animal data using routine computational methods. In one embodiment, the prophylactically effective dose contains between about 0.1 mg and about 1 g of the instant DNAzyme. In another embodiment, the prophylactically effective dose contains between about 1 mg and about 100 mg of the instant DNAzyme. In a further embodiment, the prophylactically effective dose contains between about 10 mg and about 50 mg of the instant DNAzyme. In yet a further embodiment, the prophylactically effective does contains about 25 mg of the instant DNAzyme.

In a sixth aspect the present invention provides an angioplastic stent for inhibiting the onset of restenosis, which comprises an angioplastic stent operably coated with a prophylactically effective dose of a DNAzyme according to the first aspect.

Angioplastic stents, also known by other terms such as "intravascular stents" or simple "stents", are well known in the art. They are routinely used to prevent vascular closure due to physical anomalies such as unwanted inward growth of vascular tissue due to surgical trauma. They often have a

tubular, expanding lattice-type structure appropriate for their function, and can optionally be biodegradable.

In this invention, the stent can be operably coated with the instant pharmaceutical composition using any suitable means known in the art. Here, "operably coating" a stent means coating it in a way that permits the timely release of the pharmaceutical composition into the surrounding tissue to be treated once the coated stent is administered. Such coating methods, for example, can use the polymer polypyrrole.

In a seventh aspect, the present invention provides a method for inhibiting the onset of restenosis in a subject undergoing angioplasty, which comprises topically administering a stent according to the fifth aspect to the subject at around the time of the angioplasty.

As used herein, administration "at around the time of angioplasty" can be performed during the procedure, or immediately before or after the procedure. The administering can be performed according to known methods such as catheter delivery.

In order that the nature of the present invention may be more clearly understood, preferred forms thereof will now be described with reference to the following non-limiting Figures and Examples.

Table 1

```
Symbol comparison table: GenRunData:pileupdna.cmp  CompCheck: 6876
                GapWeight: 5.000
           GapLengthWeight: 0.300
EGR1align.msf  MSF: 4388  Type: N  April  7, 1998 12:07  Check: 5107

Name: mouseEGR1  Len:  4388  Check: 8340  Weight: 1.0(SEQ ID NO:11)
Name: ratEGR1    Len:  4388  Check: 8587  Weight: 1.0(SEQ ID NO:12)
Name: humanEGR1 Len:  4388  Check: 8180  Weight:  1.00 (SEQ ID NO:1)
```

NB. THIS IS RAT NGFI-A numbering

```
                1                                                   50
mouseEgr1       ..........  ..........  ..........  ..........  ..........
  ratNGFIA      CCGCGGAGCC  TCAGCTCTAC  GCGCCTGGCG  CCCTCCCTAC  GCGGGCGTCC
humanEGR1       ..........  ..........  ..........  ..........  ..........

               51                                                  100
mouseEGR1       ..........  ..........  ..........  ..........  ..........
  ratEGR1       CCGACTCCCG  CGCGCGTTCA  GGCTCCGGGT  TGGGAACCAA  GGAGGGGGAG
humanEGR1       ..........  ..........  ..........  ..........  ..........

              101                                                  150
mouseEGR1       ..........  ..........  ..........  ..........  ..........
  ratEGR1       GGTGGGTGCG  CCGACCCGGA  AACACCATAT  AAGGAGCAGG  AAGGATCCCC
humanEGR1       ..........  ..........  ..........  ..........  ..........

              151                                                  200
mouseEGR1       ..........  ..........  ..........  ..........  ..........
  ratEGR1       CGCCGGAACA  GACCTTATTT  GGGCAGCGCC  TTATATGGAG  TGGCCCAATA
humanEGR1       ..........  ..........  ..........  ..........  ..........

              201                                                  250
mouseEGR1       ..........  ..........  ..........  ..........  ..........
  ratEGR1       TGGCCCTGCC  GCTTCCGGCT  CTGGGAGGAG  GGGCGAACGG  GGGTTGGGGC
humanEGR1       ..........  ..........  ..........  ..........  ..........

              251                                                  300
mouseEGR1       ..........  ..........  ..........  ..........  ..........
  ratEGR1       GGGGGCAAGC  TGGGAACTCC  AGGAGCCTAG  CCCGGGAGGC  CACTGCCGCT
humanEGR1       ..........  ..........  ..........  ..........  ..........

              301                                                  350
mouseEGR1       ..........  ..........  ..........  ..........  ..........
  ratEGR1       GTTCCAATAC  TAGGCTTTCC  AGGAGCCTGA  GCGCTCAGGG  TGCCGGAGCC
humanEGR1       ..........  ..........  ..........  ..........  ..........

              351                                                  400
mouseEGR1       ..........  ..........  ..........  ..........  ..........
  ratEGR1       GGTCGCAGGG  TGGAAGCGCC  CACCGCTCTT  GGATGGGAGG  TCTTCACGTC
humanEGR1       ..........  ..........  ..........  ..........  ..........

              401                                                  450
mouseEGR1       ..........  ..........  ..........  ..........  ..........
  ratEGR1       ACTCCGGGTC  CTCCCGGTCG  GTCCTTCCAT  ATTAGGGCTT  CCTGCTTCCC
humanEGR1       ..........  ..........  ..........  ..........  ..........

              451                                                  500
```

```
mouseEGR1  .......... .......... .......... .......... ..........
  ratEGR1  ATATATGGCC ATGTACGTCA CGGCGGAGGC GGGCCCGTGC TGTTTCAGAC
humanEGR1  .......... .......... .......... .......... ..........

           501                                                  550
mouseEGR1  .......... .......... .......... .......... ..........
  ratEGR1  CCTTGAAATA GAGGCCGATT CGGGGAGTCG CGAGAGATCC CAGCGCGCAG
humanEGR1  .......... .......... .......... .......... ....CCGCAG

           551                                                  600
mouseEGR1  .....GGGGA GCCGCCGCCG CGATTCGCCG CCGCCGCCAG CTTCCGCCGC
  ratEGR1  AACTTGGGGA GCCGCCGCCG CGATTCGCCG CCGCCGCCAG CTTCCGCCGC
humanEGR1  AACTTGGGGA GCCGCCGCCG CCATCCGCCG CCGCAGCCAG CTTCCGCCGC

           601                                                  650
mouseEGR1  CGCAAGATCG GCCCCTGCCC CAGCCTCCGC GGCAGCCCTG CGTCCACCAC
  ratEGR1  CGCAAGATCG GCCCCTGCCC CAGCCTCCGC GGCAGCCCTG CGTCCACCAC
humanEGR1  CGCAGGACCG GCCCCTGCCC CAGCCTCCGC AGCCGCGGCG CGTCCACGCC

           651                                                  700
mouseEGR1  GGGCCGCGGC TACCGCCAGC CTGGGGGCCC ACCTACACTC CCCGCAGTGT
  ratEGR1  GGGCCGCGGC CACCGCCAGC CTGGGGGCCC ACCTACACTC CCCGCAGTGT
humanEGR1  CGCCCGCGCC CAGGGCGAGT CGGGGTCGCC GCCTGCACGC TTCTCAGTGT

           701                                                  750
mouseEGR1  GCCCCTGCAC CCCGCATGTA ACCCGGCCAA CCCCCGGCGA GTGTGCCCTC
  ratEGR1  GCCCCTGCAC CCCGCATGTA ACCCGGCCAA CATCCGGCGA GTGTGCCCTC
humanEGR1  TCCCC.GCGC CCCGCATGTA ACCCGGCCAG GCCCCCGCAA CGGTGTCCCC

           751                                                  800
mouseEGR1  AGTAGCTTCG GCCCCGGGCT GCGCCCACC. .ACCCAACAT CAGTTCTCCA
  ratEGR1  AGTAGCTTCG GCCCCGGGCT GCGCCCACC. .ACCCAACAT CAGCTCTCCA
humanEGR1  TGCAGCTCCA GCCCCGGGCT GCACCCCCCC GCCCCGACAC CAGCTCTCCA

           801                                                  850
mouseEGR1  GCTCGCTGGT CCGGGATGGC AGCGGCCAAG GCCGAGATGC AATTGATGTC
  ratEGR1  GCTCGCACGT CCGGGATGGC AGCGGCCAAG GCCGAGATGC AATTGATGTC
humanEGR1  GCCTGCTCGT CCAGGATGGC CGCGGCCAAG GCCGAGATGC AGCTGATGTC

           ED5 (rat) arms hybridise to bp 807-825 in rat sequ
           hED5(hum) arms hybridise to bp 262-280 in hum sequ

           851                                                  900
mouseEGR1  TCCGCTGCAG ATCTCTGACC CGTTCGGCTC CTTTCCTCAC TCACCCACCA
  ratEGR1  TCCGCTGCAG ATCTCTGACC CGTTCGGCTC CTTTCCTCAC TCACCCACCA
humanEGR1  CCCGCTGCAG ATCTCTGACC CGTTCGGATC CTTTCCTCAC TCGCCCACCA

           901                                                  950
mouseEGR1  TGGACAACTA CCCCAAACTG GAGGAGATGA TGCTGCTGAG CAACGGGGCT
  ratEGR1  TGGACAACTA CCCCAAACTG GAGGAGATGA TGCTGCTGAG CAACGGGGCT
humanEGR1  TGGACAACTA CCCTAAGCTG GAGGAGATGA TGCTGCTGAG CAACGGGGCT

           951                                                 1000
mouseEGR1  CCCCAGTTCC TCGGTGCTGC CGGAACCCCA GAGGGCAGCG GCGGTAAT..
  ratEGR1  CCCCAGTTCC TCGGTGCTGC CGGAACCCCA GAGGGCAGCG GCGGCAATAA
humanEGR1  CCCCAGTTCC TCGGCGCCGC CGGGGCCCCA GAGGGCAGCG GCAGCAACAG

           1001                                                1050
mouseEGR1  .......AGC AGCAGCAGCA CCAGCAGCGG GGGCGGTGGT GGGGGCGGCA
  ratEGR1  CAGCAGCAGC AGCAGCAGCA GCAGCAGCGG GGGCGGTGGT GGGGGCGGCA
```

```
humanEGR1  CAGCAGCAGC AGCAGCGGGG GCGGTGGAGG CGGCGGGGGC GGCAGCAACA

                1051                                          1100
mouseEGR1  GCAACAGCGG CAGCAGCGCC TTCAATCCTC AAGGGGAGCC GAGCGAACAA
  ratEGR1  GCAACAGCGG CAGCAGCGCT TTCAATCCTC AAGGGGAGCC GAGCGAACAA
humanEGR1  GCAGCAGCAG CAGCAGCACC TTCAACCCTC AGGCGGACAC GGGCGAGCAG

                1101                                          1150
mouseEGR1  CCCTATGAGC ACCTGACCAC AG...AGTCC TTTTCTGACA TCGCTCTGAA
  ratEGR1  CCCTACGAGC ACCTGACCAC AGGTAAGCGG TGGTCTGCGC CGAGGCTGAA
humanEGR1  CCCTACGAGC ACCTGACCGC AG...AGTCT TTTCCTGACA TCTCTCTGAA

                1151                                          1200
mouseEGR1  TAATGAGAAG GCGATGGTGG AGACGAGTTA TCCCAGCCAA ACGACTCGGT
  ratEGR1  TCCCCCTTCG TGACTACCCT AACGTCCAGT CCTTTGCAGC ACGGACCTGC
humanEGR1  CAACGAGAAG GTGCTGGTGG AGACCAGTTA CCCCAGCCAA ACCACTCGAC

                1201                                          1250
mouseEGR1  TGCCTCCCAT CACCTATACT GGCCGCTTCT CCCTGGAGCC CGCACCCAAC
  ratEGR1  ATCTAGATCT TAGGGACGGG ATTGGGATTT CCCTCTATTC ..CACACAGC
humanEGR1  TGCCCCCCAT CACCTATACT GGCCGCTTTT CCCTGGAGCC TGCACCCAAC

                1251                                          1300
mouseEGR1  AGTGGCAACA CTTTGTGGCC TGAACCCCTT TTCAGCCTAG TCAGTGGCCT
  ratEGR1  TCCAGGGACT TGTGTTAGAG GGATGTCTGG GGACCCCCCA ACCCTCCATC
humanEGR1  AGTGGCAACA CCTTGTGGCC CGAGCCCCTC TTCAGCTTGG TCAGTGGCCT

                1301                                          1350
mouseEGR1  CGTGAGCATG ACCAATCCTC CGACCTCTTC ATCCTCGGCG CCTTCTCCAG
  ratEGR1  CTTGCGGGTG CGCGGAGGGC AGACCGTTTG TTTTGGATGG AGAACTCAAG
humanEGR1  AGTGAGCATG ACCAACCCAC CGGCCTCCTC GTCCTCAGCA CCATCTCCAG

                1351                                          1400
mouseEGR1  CTGCTTCATC GTCTTCCTCT GCCTCCCAGA GCCCGCCCCT GAGCTGTGCC
  ratEGR1  TTGCGTGGGT GGCT...... .....GGAGT GGGGGAGGGT TTGTTTTGAT
humanEGR1  CGGCCTCCTC CGC...CTCC GCCTCCCAGA GCCCACCCCT GAGCTGCGCA

                1401                                          1450
mouseEGR1  GTGCCGTCCA ACGACAGCAG TCCCATCTAC TCGGCTGCGC CCACCTTTCC
  ratEGR1  GAGCAGGGTT GC....CCCC TCCCCCGCGC GCGTTGTCGC GAGCCTTGTT
humanEGR1  GTGCCATCCA ACGACAGCAG TCCCATTTAC TCAGCGGCAC CCACCTTCCC

                1451                                          1500
mouseEGR1  TACTCCCAAC ACTGACATTT TTCCTGAGCC CCAAAGCCAG GCCTTTCCTG
  ratEGR1  TGCAGCTTGT TCCCAAGGAA GGGCTGAAAT CTGTCACCAG GGATGTCCCG
humanEGR1  CACGCCGAAC ACTGACATTT TCCCTGAGCC ACAAAGCCAG GCCTTCCCGG

                1501                                          1550
mouseEGR1  GCTCGGCAGG CACAGCCTTG CAGTACCCGC CTCCTGCCTA CCCTGCCACC
  ratEGR1  CCGCCCAGGG TAGGGGCGCG CATTAGCTGT GGCC.ACTAG GGTGCTGGCG
humanEGR1  GCTCGGCAGG GACAGCGCTC CAGTACCCGC CTCCTGCCTA CCCTGCCGCC

                1551                                          1600
mouseEGR1  AAAGGTGGTT TCCAGGTTCC CATGATCCCT GACTATCTGT TTCCACAACA
  ratEGR1  GGATTCCCTC ACCCCGGACG CCTGCTGCGG AGCGCTCTCA GAGCTGCAGT
humanEGR1  AAGGGTGGCT TCCAGGTTCC CATGATCCCC GACTACCTGT TTCCACAGCA

                1601                                          1650
mouseEGR1  ACAGGGAGAC CTGAGCCTGG GCACCCCAGA CCAGAAGCCC TTCCAGGGTC
  ratEGR1  AGAGGGGGAT TCTCTGTTTG CGTCAGCTGT CGAAATGGCT CT......GC
```

```
humanEGR1  GCAGGGGGAT CTGGGCCTGG GCACCCCAGA CCAGAAGCCC TTCCAGGGCC

           1651                                                1700
mouseEGR1  TGGAGAACCG TACCCAGCAG CCTTCGCTCA CTCCACTATC CACTATTAAA
ratEGR1    CACTGGAGCA GGTCCAGGAA CATTGCAATC TGCTGCTATC AATTATTAAC
humanEGR1  TGGAGAGCCG CACCCAGCAG CCTTCGCTAA CCCCTCTGTC TACTATTAAG

           1701                                                1750
mouseEGR1  GCCTTCGCCA CTCAGTCGGG CTCCCAGGAC TTAAAG.... ...GCTCTTA
ratEGR1    CACATCGAGA GTCAGTGGTA GCCGGGCGAC CTCTTGCCTG GCCGCTTCGG
humanEGR1  GCCTTTGCCA CTCAGTCGGG CTCCCAGGAC CTGAAG.... ...GCCCTCA

           1751                                                1800
mouseEGR1  ATACCACCTA CCAATCCCAG CTCATCA..A ACCCAGCCGC ATGCGCAAGT
ratEGR1    CTCTCATCGT CCAGTGATTG CTCTCCAGTA ACCAGGCCTC TCTGTTCTCT
humanEGR1  ATACCAGCTA CCAGTCCCAG CTCATCA..A ACCCAGCCGC ATGCGCAAGT

           1801                                                1850
mouseEGR1  ACCCCAACCG GCCCAGCAAG ACACCCCCCC ATGAACGCCC ATATGCTTGC
ratEGR1    TTCCTGCCAG AGTCCTTTTC TGACATCGCT CTGAATAACG AGAAG..GCG
humanEGR1  ATCCCAACCG GCCCAGCAAG ACGCCCCCCC ACGAACGCCC TTACGCTTGC

           1851                                                1900
mouseEGR1  CCTGTCGAGT CCTGCGATCG CCGCTTTTCT CGCTCGGATG AGCTTACCCG
ratEGR1    CTGGTGGAGA CAAGTTATCC CAGCCAAACT ACCCGGTTGC CTCCCATCAC
humanEGR1  CCAGTGGAGT CCTGTGATCG CCGCTTCTCC CGCTCCGACG AGCTCACCCG

           1901                                                1950
mouseEGR1  CCATATCCGC ATCCACACAG GCCAGAAGCC CTTCCAGTGT CGAATCTGCA
ratEGR1    CTATACTGGC CGCTTCTCCC TGGAGCCTGC ACCCAACAGT GGCAACACTT
humanEGR1  CCACATCCGC ATCCACACAG GCCAGAAGCC CTTCCAGTGC CGCATCTGCA

           1951                                                2000
mouseEGR1  TGCGTAACTT CAGTCGTAGT GACCACCTTA CCACCCACAT CCGCACCCAC
ratEGR1    TGTGGCCTGA ACCCCTTTTC AGCCTAGTCA GTGGCCTTGT GAGCATGACC
humanEGR1  TGCGCAACTT CAGCCGCAGC GACCACCTCA CCACCCACAT CCGCACCCAC

           2001                                                2050
mouseEGR1  ACAGGCGAGA AGCCTTTTGC CTGTGACATT TGTGGGAGGA AGTTTGCCAG
ratEGR1    AACCCTCCAA CCTCTTCATC CTCAGCGCCT TCTCCAGCTG CTTCATCGTC
humanEGR1  ACAGGCGAAA AGCCCTTCGC CTGCGACATC TGTGGAAGAA AGTTTGCCAG

           2051                                                2100
mouseEGR1  GAGTGATGAA CGCAAGAGGC ATACCAAAAT CCATTTAAGA CAGAAGGACA
ratEGR1    TTCCTCTGCC TCCCAGAGCC CACCCCTGAG CTGTGCCGTG CCGTCCAACG
humanEGR1  GAGCGATGAA CGCAAGAGGC ATACCAAGAT CCACTTGCGG CAGAAGGACA

           2101                                                2150
mouseEGR1  AGAAAGCAGA CAAAAGTGTG GTGGCCTCCC CGGCTGC... .CTCTTCACT
ratEGR1    ACAGCAGTCC CATTTACTCA GCTGCACCCA CCTTTCCTAC TCCCAACACT
humanEGR1  AGAAAGCAGA CAAAAGTGTT GTGGCCTCTT CGGCCACCTC CTCTCTCTCT

           2151                                                2200
mouseEGR1  .......... .......... CTCTTCTTAC CCATCCCCAG TGGCTACCTC
ratEGR1    .......... .......... GACATTTTTC CTGAGCCCCA AAGCCAGGCC
humanEGR1  TCCTACCCGT CCCCGGTTGC TACCTCTTAC CCGTCCCCGG TTACTACCTC

           2201                                                2250
mouseEGR1  CTACCCATCC CCTGCCACCA CCTCATTCCC ATCCCCTGTG CCCACTTCCT
ratEGR1    TTTCCTGGCT CTGCAGGCAC AGCCTTGCAG TACCCGCCTC CTGCCTACCC
```

```
humanEGR1  TTATCCATCC CCGGCCACCA CCTCATACCC ATCCCCTGTG CCCACCTCCT

           2251                                                2300
mouseEGR1  ACTCCTCTCC TGGCTCCTCC ACCTACCCAT CTCCTGCGCA CAGTGGCTTC
ratEGR1    TGCCACCAAG GGTGGTTTCC AGGTTCCCAT GATCCCTGAC TATCTGTTTC
humanEGR1  TCTCCTCTCC CGGCTCCTCG ACCTACCCAT CCCCTGTGCA CAGTGGCTTC

           2301                                                2350
mouseEGR1  CCGTCGCCGT CAGTGGCCAC CACCTTTGCC TCCGTTCC.. ..........
ratEGR1    CACAACAACA GGGAGACCTG AGCCTGGGCA CCCCAGACCA GAAGCCCTTC
humanEGR1  CCCTCCCCGT CGGTGGCCAC CACGTACTCC TCTGTTCCC. ..........

           2351                                                2400
mouseEGR1  ....ACCTGC TTTCCCCACC CAGGTCAGCA GCTTCCCGTC TGCGGGCGTC
ratEGR1    CAGGGTCTGG AGAACCGTAC CCAGCAGCCT TCGCTCACTC CACTATCCAC
humanEGR1  .....CCTGC TTTCCCGGCC CAGGTCAGCA GCTTCCCTTC CTCAGCTGTC

           2401                                                2450
mouseEGR1  AGCAGCTCCT TCAGCACCTC AACTGGTCTT TCAGACATGA CAGCGACCTT
ratEGR1    TATCAAAGCC TTCGCCACTC AGTCGGGCTC CCAGGACTTA AAGGCTCTTA
humanEGR1  ACCAACTCCT TCAGCGCCTC CACAGGGCTT TCGGACATGA CAGCAACCTT

           2451                                                2500
mouseEGR1  TTCTCCCAGG ACAATTGAAA TTTGCTAAAG GGA..... .ATAAAAG..
ratEGR1    ATAACACCTA CCAGTCCCAA CTCATCAAAC CCAGCCGCAT GCGCAAGT..
humanEGR1  TTCTCCCAGG ACAATTGAAA TTTGCTAAAG GGAAAGGGGA AAGAAAGGGA

           2501                                                2550
mouseEGR1  .AAAGCAAAG GGAGAGGCAG GAAAGACATA AAAGCA...C AGGAGGGAAG
ratEGR1    .ACCCCAACC GGCCCAGCAA GACACCCCCC CATGAACGCC CGTATGCTTG
humanEGR1  AAAGGGAGAA AAAGAAACAC AAGAGACTTA AAGGACAGGA GGAGGAGATG

           2551                                                2600
mouseEGR1  AGATGGCCGC AAGAGGGGCC ACCTCTTAGG TCAGATGGAA GATCTCAGAG
ratEGR1    CCCTGTTGAG TCCTGCGATC GCCGCTTTTC TCGCTCGGAT GAGCTTACAC
humanEGR1  GCCATAGGAG AGGAGGGTT. .CCTCTTAGG TCAGATGGAG GTTCTCAGAG

           2601                                                2650
mouseEGR1  CCAAGTCCTT CTACTCACGA GTA..GAAGG ACCGTTGGCC AACAGCCCTT
ratEGR1    GCCACATCCG CATCCATACA GGC..CAGAA GCCCTTCCAG TGTCGAATCT
humanEGR1  CCAAGTCCTC CCTCTCTACT GGAGTGGAAG GTCTATTGGC CAACAATCCT

           2651                                                2700
mouseEGR1  TCACTTACCA TCCCTGCCTC CCCCGTCCTG TTCCCTTTGA CTTCAGCTGC
ratEGR1    GCATGCGTAA TTTCAGTCGT AGTGACCACC TTACCACCCA CATCCGCACC
humanEGR1  TTCTGCCCAC TTCCCCTTCC CCAATTACTA TTCCCTTTGA CTTCAGCTGC

           2701                                                2750
mouseEGR1  CTGAAACAGC CATGTCCAAG TTCTTCACCT CTATCCAAAG GACTTGATTT
ratEGR1    C..ACACAGG CGAGAAGCCT TTTGCCTGTG ACATTTGTGG GAGAAAGTTT
humanEGR1  CTGAAACAGC CATGTCCAAG TTCTTCACCT CTATCCAAAG AACTTGATTT

           2751                                                2800
mouseEGR1  GCATGG.... ..TATTGGAT AAATCATTTC AGTATCCTCT ..........
ratEGR1    GCCAGGAGTG ATGAACGCAA GAGGCATACC AAAATCCACT TAAGACAGAA
humanEGR1  GCATGGA... ..TTTTGGAT AAATCATTTC AGTATCATCT ..........

           2801                                                2850
mouseEGR1  .....CCATC ACATGCCTGG CCCTTGCTCC CTTCAGCGCT AGACCATCAA
ratEGR1    GGACAAGAAA GCAGACAAAA GTGTCGTGGC CTCCTCAGCT GCCTCTTCCC
```

```
humanEGR1  ....CCATCA TATGCCTGAC CCCTTGCTCC CTTCAATGCT AGAAAATCGA

           2851                                                2900
mouseEGR1  GTTGGCATAA AGAAAAAAAA ATGGGTTTGG GCCCTCAGAA CCCTGCCCTG
ratEGR1    TCTCTTCCTA CCCATCCCCA GTGGCTACCT CCTACCCATC CCCCGCCACC
humanEGR1  GTTGGC.... .....AAAAT GGGGTTTGGG CCCCTCAGAG CCCTGCCCTG

           2901                                                2950
mouseEGR1  CATCTTTGTA CAGCATCTGT GCCATGGATT TTGTTTTCCT TGGGGTATTC
ratEGR1    ACCTCATTTC CATCCCCAGT GCCCACCTCT TACTCCTCTC CGGGCTCCTC
humanEGR1  CACCCTTGTA CAGTGTCTGT GCCATGGATT TCGTTTTTCT TGGGGTACTC

           2951                                                3000
mouseEGR1  TTGATGTGAA GATAATTTGC ATACT..... .CTATTGTAT TATTTGGAGT
ratEGR1    TACCTACCCG TCTCCTGCAC ACAGTGGCTT CCCATCGCCC TCGGTGGCCA
humanEGR1  TTGATGTGAA GATAATTTGC ATATT..... .CTATTGTAT TATTTGGAGT

           3001                                                3050
mouseEGR1  TAAATCCTCA CTTTGGGG.. GAGGGGGGAG CAAAGCCAAG CAAACCAATG
ratEGR1    CCACCTATGC CTCCGTCC.. CACCTGCTTT CCCTGCCCAG GTCAGCACCT
humanEGR1  TAGGTCCTCA CTTGGGGGAA AAAAAAAAAA AAAAGCCAAG CAAACCAATG

           3051                                                3100
mouseEGR1  ATGATCCTCT ATTTTGTGAT GACTCTGCTG TGACATTA.. ..........
ratEGR1    TCCAGTCTGC AGGGGTCAGC AACTCCTTCA GCACCTCAAC GGGTCTTTCA
humanEGR1  GTGATCCTCT ATTTTGTGAT GATGCTGTGA CAATA..... ..........

           3101                                                3150
mouseEGR1  .GGTTTGAAG CATTTTTTTT TTCAAGCAGC AGTCCTAGGT ATTAACTGGA
ratEGR1    GACATGACAG CAACCTTTTC TCCTAGGACA ATTGAAATTT GCTAAAGGGA
humanEGR1  ...AGTTTGA ACCTTTTTTT TTGAAACAGC AGTCCCAG.. ..TATTCTCA

           3151                                                3200
mouseEGR1  ..GCATGTGT CAGAGTGTTG TTCCGTTAAT TTTGTAAATA CTGGCTCGAC
ratEGR1    ATGAAAGAGA GCAAAGGGAG GGGAGCGCGA GAGACAATAA AGGACAGGAG
humanEGR1  GAGCATGTGT CAGAGTGTTG TTCCGTTAAC CTTTTTGTAA ATACTGCTTG

           3201                                                3250
mouseEGR1  .TGTAACTCT CACATGTGAC AAAGTATGGT TTGTTTGGTT GGGTTTTGTT
ratEGR1    .GGAAGAAAT GGCCCGCAAG AGGGGCTGCC TCTTAGGTCA GATGGAAGAT
humanEGR1  ACCGTACTCT CACATGTGGC AAAATATGGT TTGGTTTTTC TTTTTTTTTT

           3251                                                3300
mouseEGR1  TTTGAGAATT TTTTTGCCCG TCCCTTTGGT TTCAAAAGTT TCACGTCTTG
ratEGR1    CTCAGAGCCA AGTCCTTCTA GTCAGTAGAA GGCCCGTTGG CCACCAGCCC
humanEGR1  TTGAAAGTGT TTTTTCTTCG TCCTTTTGGT TTAAAAAGTT TCACGTCTTG

           3301                                                3350
mouseEGR1  GTGCCTTTTG TGTGACACGC CTT.CCGATG GCTTGACATG CGCA......
ratEGR1    TTTCACTTAG CGTCCCTGCC CTC.CCCAGT CCCGGTCCTT TTGACTTCAG
humanEGR1  GTGCCTTTTG TGTGATGCCC CTTGCTGATG GCTTGACATG TGCAAT....

           3351                                                3400
mouseEGR1  ...GATGTGA GGGACACGCT CACCTTAGCC TTAA...GGG GGTAGGAGTG
ratEGR1    CTGCCTGAAA CAGCCACGTC CAAGTTCTTC ACCT...CTA TCCAAAGGAC
humanEGR1  .....TGTGA GGGACATGCT CACCTCTAGC CTTAAGGGGG GCAGGGAGTG

           3401                                                3450
mouseEGR1  ATGTGTTGGG GGAGGCTTGA GAGCAAAAAC GAGGAAGAGG GCTGAGCTGA
ratEGR1    TTGATTTGCA TGGTATTGGA TAAACCATTT CAGCATCATC TCCACCACAT
```

```
humanEGR1  ATGATTTGGG GGAGGCTTTG GGAGCAAAAT AAGGAAGAGG GCTGAGCTGA

           3451                                                 3500
mouseEGR1  GCTTTCGGTC TCCAGAATGT AAGAAGAAAA AATTTAAACA AAAATCTGAA
ratEGR1    GCCTGGCCCT TGCTCCCTTC AGCACTAGAA CATCAAGTTG GCTGAAAAAA
humanEGR1  GCTTCGGTTC TCCAGAATGT AAGAAAACAA AATCTAAAAC AAAATCTGAA

           3501                                                 3550
mouseEGR1  CTCTCAAAAG TCTATTTTTC TAAACTGAAA ATGTAAATTT ATACATCTAT
ratEGR1    AAAATGGGTC TGGGCCCTCA GAACCCTGCC CTGTATCTTT GTACA.....
humanEGR1  CTCTCAAAAG TCTATTTTTT TAA.CTGAAA ATGTAAATTT ATAAATATAT

           3551                                                 3600
mouseEGR1  TCAGGAGTTG GAGTGTTGTG GTTACCTACT GAGTAGGCTG CAGTTTTTGT
ratEGR1    GCATCTGTGC CATGGATTTT GTTTTCCTTG GGGTATTCTT GATGTGAAGA
humanEGR1  TCAGGAGTTG GAATGTTGTA GTTACCTACT GAGTAGGCGG CGATTTTTGT

           3601                                                 3650
mouseEGR1  ATGTTATGAA CATGAAGTTC ATTATTTTGT GGTTTTATTT TACTTTGTAC
ratEGR1    TAATTTGCAT ACTCTATTGT ACTATTTGGA GTTAAATTCT CACTTTGGGG
humanEGR1  ATGTTATGAA CATGCAGTTC ATTATTTTGT GGTTCTATTT TACTTTGTAC

           3651                                                 3700
mouseEGR1  TTGTGTTTGC TTAAACAAAG TAACCTGTTT GGCTTATAAA CACATTGAAT
ratEGR1    GAGGGGGAGC AAAGCCAAGC AAACCAATGG TGATCCTCTA TTTTGTGATG
humanEGR1  TTGTGTTTGC TTAAACAAAG TGA.CTGTTT GGCTTATAAA CACATTGAAT

           3701                                                 3750
mouseEGR1  GCGCTCTATT GCCCATGG.. ..GATATGTG GTGTGTATCC TTCAGAAAAA
ratEGR1    ATCCTGCTGT GACATTAGGT TTGAAACTTT TTTTTTTTTT TGAAGCAGCA
humanEGR1  GCGCTTTATT GCCCATGG.. ..GATATGTG GTGTATATCC TTCCAAAAAA

           3751                                                 3800
mouseEGR1  TTAAAAGGAA AAAT..... ..........  .......... ..........
ratEGR1    GTCCTAGGTA TTAACTGGAG CATGTGTCAG AGTGTTGTTC CGTTAATTTT
humanEGR1  TTAAAACGAA AATAAAGTAG CTGCGATTGG G.........  ..........

           3801                                                 3850
mouseEGR1  ..........  ..........  ..........  ..........  ..........
ratEGR1    GTAAATACTG CTCGACTGTA ACTCTCACAT GTGACAAAAT ACGGTTTGTT
humanEGR1  ..........  ..........  ..........  ..........  ..........

           3851                                                 3900
mouseEGR1  ..........  ..........  ..........  ..........  ..........
ratEGR1    TGGTTGGGTT TTTTGTTGTT TTTGAAAAAA AAATTTTTTT TTTGCCCGTC
humanEGR1  ..........  ..........  ..........  ..........  ..........

           3901                                                 3950
mouseEGR1  ..........  ..........  ..........  ..........  ..........
ratEGR1    CCTTTGGTTT CAAAAGTTTC ACGTCTTGGT GCCTTTGTGT GACACACCTT
humanEGR1  ..........  ..........  ..........  ..........  ..........

           3951                                                 4000
mouseEGR1  ..........  ..........  ..........  ..........  ..........
ratEGR1    GCCGATGGCT GGACATGTGC AATCGTGAGG GGACACGCTC ACCTCTAGCC
humanEGR1  ..........  ..........  ..........  ..........  ..........

           4001                                                 4050
mouseEGR1  ..........  ..........  ..........  ..........  ..........
ratEGR1    TTAAGGGGGT AGGAGTGATG TTTCAGGGGA GGCTTTAGAG CACGATGAGG
```

```
          humanEGR1  .......... .......... .......... .......... ..........

                     4051                                                4100
          mouseEGR1  .......... .......... .......... .......... ..........
             ratEGR1 AAGAGGGCTG AGCTGAGCTT TGGTTCTCCA GAATGTAAGA AGAAAAATTT
          humanEGR1  .......... .......... .......... .......... ..........

                     4101                                                4150
          mouseEGR1  .......... .......... .......... .......... ..........
             ratEGR1 AAAACAAAAA TCTGAACTCT CAAAAGTCTA TTTTTTTAAC TGAAAATGTA
          humanEGR1  .......... .......... .......... .......... ..........

                     4151                                                4200
          mouseEGR1  .......... .......... .......... .......... ..........
             ratEGR1 GATTTATCCA TGTTCGGGAG TTGGAATGCT GCGGTTACCT ACTGAGTAGG
          humanEGR1  .......... .......... .......... .......... ..........

                     4201                                                4250
          mouseEGR1  .......... .......... .......... .......... ..........
             ratEGR1 CGGTGACTTT TGTATGCTAT GAACATGAAG TTCATTATTT TGTGGTTTTA
          humanEGR1  .......... .......... .......... .......... ..........

                     4251                                                4300
          mouseEGR1  .......... .......... .......... .......... ..........
             ratEGR1 TTTTACTTCG TACTTGTGTT TGCTTAAACA AAGTGACTTG TTTGGCTTAT
          humanEGR1  .......... .......... .......... .......... ..........

                     4301                                                4350
          mouseEGR1  .......... .......... .......... .......... ..........
             ratEGR1 AAACACATTG AATGCGCTTT ACTGCCCATG GGATATGTGG TGTGTATCCT
          humanEGR1  .......... .......... .......... .......... ..........

                     4351                                     4388
          mouseEGR1  .......... .......... .......... ........
             ratEGR1 TCAGAAAAAT TAAAAGGAAA ATAAAGAAAC TAACTGGT
          humanEGR1  .......... .......... .......... ........
```

Example 1

Characterisation of DNAzymes ED5 and hED5

Materials and Methods

ODN synthesis. DNAzymes were synthesized commercially (Oligos Etc., Inc.) with an inverted T at the 3' position unless otherwise indicated. Substrates in cleavage reactions were synthesized with no such modification. Where indicated ODNs were 5'-end labeled with γ^{32}P-dATP and T4 polynucleotide kinase (New England Biolabs). Unincorporated label was separated from radiolabeled species by centrifugation on Chromaspin-10 columns (Clontech).

In vitro transcript and cleavage experiments. A ^{32}P-labelled 206 nt NGFI-A RNA transcript was prepared by in vitro transcription (T3 polymerase) of plasmid construct pJDM8 (as described in Milbrandt, 1987, the entire contents of which are incorporated herein by reference) previously cut with *Bgl* II. Reactions were performed in a total volume of 20 μl containing 10 mM $MgCl_2$, 5 mM Tris pH 7.5, 150 mM NaCl, 4.8 pmol of in vitro transcribed or synthetic RNA substrate and 60 pmol DNAzyme (1:12.5 substrate to DNAzyme ratio), unless otherwise indicated. Reactions were allowed to proceed at 37 °C for the times indicated and quenched by transferring an aliquot to tubes containing formamide loading buffer (Sambrook et al, 1989). Samples were run on 12% denaturing polyacrylamide gels and autoradiographed overnight at -80 °C.

Culture conditions and DNAzyme transfection. Primary rat aortic SMCs were obtained from Cell Applications, Inc., and grown in Waymouth's medium, pH 7.4, containing 10% fetal bovine serum (FBS), 50 μg/ml streptomycin and 50 IU/ml penicillin at 37 °C in a humidified atmosphere of 5% CO_2. SMCs were used in experiments between passages 3-7. Pup rat SMCs (WKY12-22 (as described in Lemire et al, 1994, the entire contents of which are incorporated herein by reference)) were grown under similar conditions. Subconfluent (60-70%) SMCs were incubated in serum-free medium (SFM) for 6 h prior to DNAzyme (or antisense ODN, where indicated) transfection (0.1 μM) using Superfect in accordance with manufacturer's instructions (Qiagen). After 18 h, the cells were washed with phosphate-buffered saline (PBS). pH 7.4 prior to transfection a second time in 5% FBS.

Northern blot analysis. Total RNA was isolated using the TRIzol reagent (Life Technologies) and 25 μg was resolved by electrophoresis prior to transfer to Hybond-N+ membranes (NEN-DuPont). Prehybridization, hybridization with α^{32}P-dCTP-labeled Egr-1 or β-Actin cDNA, and washing was performed essentially as previously described (Khachigian et al, 1995).

Western blot analysis. Growth-quiescent SMCs in 100 mm plates (Nunc-InterMed) were transfected with ED5 or ED5SCR as above, and incubated with 5% FBS for 1 h. The cells were washed in cold PBS, pH 7.4, and extracted in 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 5 mM EDTA, 1% trasylol, 10 μg/ml leupeptin, 1% aprotinin and 2 mM PMSF. Twenty four μg protein samples were loaded onto 10% denaturing SDS-polyacrylamide gels and electroblotted onto PVDF nylon membranes (NEN-DuPont). Membranes were air dried prior to blocking with non-fat skim milk powder in PBS containing 0.05% (w:v) Tween 20. Membranes were incubated with rabbit antibodies to Egr-1 or Sp1 (Santa Cruz Biotechnology, Inc.) (1:1000) then with HRP-linked mouse anti-rabbit Ig secondary antiserum (1:2000). Where mouse monoclonal c-Fos (Santa Cruz Biotechnology, Inc.) was used, detection was achieved with HRP-linked rabbit anti-mouse Ig. Proteins were visualized by chemiluminescent detection (NEN-DuPont).

Assays of cell proliferation. Growth-quiescent SMCs in 96-well titer plates (Nunc-InterMed) were transfected with ED5 or ED5SCR as above, then exposed to 5% FBS at 37 °C for 72 h. The cells were rinsed with PBS, pH 7.4, trypsinized and the suspension was quantitated using an automated Coulter counter.

Assessment of DNAzyme stability. DNAzymes were 5'-end labeled with γ^{32}P-dATP and separated from free label by centrifugation. Radiolabeled DNAzymes were incubated in 5% FBS or serum-free medium at 37 °C for the times indicated. Aliquots of the reaction were quenched by transfer to tubes containing formamide loading buffer (Sambrook et al, 1989). Samples were applied to 12% denaturing polyacrylamide gels and autoradiographed overnight at -80 °C.

SMC wounding assay. Confluent growth-quiescent SMCs in chamber slides (Nunc-InterMed) were exposed to ED5 or ED5SCR for 18 h prior to a single scrape with a sterile toothpick. Cells were treated with mitomycin C (Sigma) (20 μM) for 2 h prior to injury (Pitsch et al, 1996; Horodyski &

Powell, 1996). Seventy-two h after injury, the cells were washed with PBS, pH 7.4, fixed with formaldehyde then stained with hematoxylin-eosin.

Rat arterial ligation model and analysis. Adult male Sprague Dawley rats weighing 300-350 g were anaesthetised using ketamine (60 mg/kg, i.p.) and xylazine (8 mg/kg, i.p.). The right common carotid artery was exposed up to the carotid bifurcation via a midline neck incision. Size 6/0 non-absorbable suture was tied around the common carotid proximal to the bifurcation, ensuring cessation of blood flow distally. A 200 μl solution at 4°C containing 500 μg of DNAzyme (in DEPC-treated H_2O), 30 μl of transfecting agent and Pluronic gel P127 (BASF) was applied around the vessel in each group of 5 rats, extending proximally from the ligature for 12-15 mm. These agents did not inhibit the solidification of the gel at 37 °C. After 3 days, vehicle with or without 500 μg of DNAzyme was administered a second time. Animals were sacrificed 18 days after ligation by lethal injection of phenobarbitone, and perfusion fixed using 10% (v:v) formaldehyde perfused at 120 mm Hg. Both carotids were then dissected free and placed in 10% formaldehyde, cut in 2 mm lengths and embedded in 3% (w:v) agarose prior to fixation in paraffin. Five μm sections were prepared at 250 μm intervals along the vessel from the point of ligation and stained with hematoxylin and eosin. The neointimal and medial areas of 5 consecutive sections per rat were determined digitally using a customized software package (Magellan) (Halasz & Martin, 1984) and expressed as a mean ratio per group of 5 rats.

Results and Discussion

The 7x7 nt arms flanking the 15 nt DNAzyme catalytic domain in the original DNAzyme design 7 were extended by 2 nts per arm for improved specificity (L.-Q. Sun, data not shown) (Figure 1). The 3' terminus of the molecule was capped with an inverted 3'-3'-linked thymidine (T) to confer resistance to 3'->5' exonuclease digestion. The sequence in both arms of ED5 was scrambled (SCR) without altering the catalytic domain to produce DNAzyme ED5SCR (Figure 1).

A synthetic RNA substrate comprised of 23 nts, matching nts 805 to 827 of NGFI-A mRNA (Figure 1) was used to determine whether ED5 had the capacity to cleave target RNA. ED5 cleaved the ^{32}P-5'-end labeled 23-mer within 10 min. The 12-mer product corresponds to the length between the

A(816)-U(817) junction and the 5' end of the substrate (Figure 1). In contrast, ED5SCR had no demonstrable effect on this synthetic substrate. Specific ED5 catalysis was further demonstrated by the inability of the human equivalent of this DNAzyme (hED5) to cleave the rat substrate over a wide range of stoichiometric ratios. Similar results were obtained using ED5SCR (data not shown). hED5 differs from the rat ED5 sequence by 3 of 18 nts in its hybridizing arms (Table 2). The catalytic effect of ED5 on a ^{32}P-labeled 206 nt fragment of native NGFI-A mRNA prepared by *in vitro* transcription was then determined. The cleavage reaction produced two radiolabeled species of 163 and 43 nt length consistent with DNAzyme cleavage at the A(816)-U(817) junction. In other experiments, ED5 also cleaved a ^{32}P-labeled NGFI-A transcript of 1960 nt length in a specific and time-dependent manner (data not shown).

Table 2. DNAzyme target sites in mRNA.

Similarity between the 18 nt arms of ED5 or hED5 and the mRNA of rat NGFI-A or human EGR-1 (among other transcription factors) is expressed as a percentage. The target sequence of ED5 in NGFI-A mRNA is 5'-807-A CGU CCG GGA UGG CAG CGG-825-3' (SEQ ID NO: 13) (rat NGFI-A sequence), and that of hED5 in EGR-1 is 5'-262-U CGU CCA GGA UGG CCG CGG-280-3' (SEQ ID NO: 14) (Human EGR-1 sequence). Nucleotides in bold indicate mismatches between rat and human sequences. Data obtained by a gap best fit search in ANGIS using sequences derived from Genbank and EMBL. Rat sequences for Sp1 and c-Fos have not been reported.

Gene	Accession number	Best homology over 18 nts (%)	
		ED5	hED5
Rat NGFI-A	M18416	**100**	84.2
Human EGR-1	X52541	84.2	**100**
Murine Sp1	AF022363	66.7	66.7
Human c-Fos	K00650	66.7	66.7
Murine c-Fos	X06769	61.1	66.7
Human Sp1	AF044026	38.9	28.9

To determine the effect of the DNAzymes on endogenous levels of NGFI-A mRNA, growth-quiescent SMCs were exposed to ED5 prior to stimulation with serum. Northern blot and densitometric analysis revealed that ED5 (0.1 μM) inhibited serum-inducible steady-state NGFI-A mRNA levels by 55% (Figure 2a), whereas ED5SCR had no effect (Figure 2a). The capacity of ED5 to inhibit NGFI-A synthesis at the level of protein was assessed by Western blot analysis. Serum-induction of NGFI-A protein was suppressed by ED5. In contrast, neither ED5SCR nor EDC, a DNAzyme bearing an identical catalytic domain as ED5 and ED5SCR but flanked by nonsense arms had any influence on the induction of NGFI-A (data not

shown). ED5 failed to affect levels of the constitutively expressed, structurally -related zinc-finger protein, Sp1. It was also unable to block serum-induction of the immediate-early gene product, c-Fos whose induction, like NGFI-A, is dependent upon serum response elements in its promoter and phosphorylation mediated by extracellular-signal regulated kinase (Treisman, 1990, 1994 and 1995; Gashler & Sukhatme, 1995). These findings, taken together, demonstrate the capacity of ED5 to inhibit production of NGFI-A mRNA and protein in a gene-specific and sequence-specific manner, consistent with the lack of significant homology between its target site in NGFI-A mRNA and other mRNA (Table 2).

The effect of ED5 on SMC replication was then determined. Growth-quiescent SMCs were incubated with DNAzyme prior to exposure to serum and the assessment of cell numbers after 3 days. ED5 (0.1 μM) inhibited SMC proliferation stimulated by serum by 70% (Figure 3a). In contrast, ED5SCR failed to influence SMC growth (Figure 3a). AS2, an antisense NGFI-A ODN able to inhibit SMC growth at 1 μM failed to inhibit proliferation at the lower concentration (Figure 3a). Additional experiments revealed that ED5 also blocked serum-inducible ^{3}H-thymidine incorporation into DNA (data not shown). ED5 inhibition was not a consequence of cell death since no change in morphology was observed, and the proportion of cells incorporating Trypan Blue in the presence of serum was not influenced by either DNAzyme (Figure 3b).

Cultured SMCs derived from the aortae of 2 week-old rats (WKY12-22) are morphologically and phenotypically similar to SMCs derived from the neointima of balloon-injured rat arteries (Seifert et al, 1984; Majesky et al, 1992). The epitheloid appearance of both WKY12-22 cells and neointimal cells contrasts with the elongated, bipolar nature of SMCs derived from normal quiescent media (Majesky et al, 1988). WKY12-22 cells grow more rapidly than medial SMCs and overexpress a large number of growth-regulatory molecules (Lemire et al, 1994), such as NGFI-A (Rafty & Khachigian, 1998), consistent with a "synthetic" phenotype (Majesky et al, 1992; Campbell & Campbell, 1985). ED5 attenuated serum-inducible WKY12-22 proliferation by approximately 75% (Figure 3c). ED5SCR had no inhibitory effect; surprisingly, it appeared to stimulate growth (Figure 3c). Trypan Blue exclusion revealed that DNAzyme inhibition was not a consequence of cytotoxicity (data not shown).

To ensure that differences in the biological effects of ED5 and ED5SCR were not the consequence of dissimilar intracellular localization, both DNAzymes were 5'-end labeled with fluorescein isothiocyanate (FITC) and incubated with SMCs. Fluorescence microscopy revealed that both FITC-ED5 and FITC-ED5SCR localized mainly within the nuclei. Punctate fluorescence in this cellular compartment was independent of DNAzyme sequence. Fluorescence was also observed in the cytoplasm, albeit with less intensity. Cultures not exposed to DNAzyme showed no evidence of autofluorescence.

Both molecules were 5'-end labeled with γ^{32}P-dATP and incubated in culture medium to ascertain whether cellular responsiveness to ED5 and ED5SCR was a consequence of differences in DNAzyme stability. Both ^{32}P-ED5 and ^{32}P-ED5SCR remained intact even after 48 h. In contrast to ^{32}P-ED5 bearing the 3' inverted T, degradation of ^{32}P-ED5 bearing its 3' T in the correct orientation was observed as early as 1 h. Exposure to serum-free medium did not result in degradation of the molecule even after 48 h. These findings indicate that inverse orientation of the 3' base in the DNAzyme protects the molecule from nucleolytic cleavage by components in serum.

Physical trauma imparted to SMCs in culture results in outward migration from the wound edge and proliferation in the denuded zone. We determined whether ED5 could modulate this response to injury by exposing growth-quiescent SMCs to either DNAzyme and Mitomycin C, an inhibitor of proliferation (Pitsch et al, 1996; Horodyski & Powell, 1996) prior to scraping. Cultures in which DNAzyme was absent repopulated the entire denuded zone within 3 days. ED5 inhibited this reparative response to injury and prevented additional growth in this area even after 6 days (data not shown). That ED5SCR had no effect in this system further demonstrates sequence-specific inhibition by ED5.

The effect of ED5 on neointima formation was investigated in a rat model. Complete ligation of the right common carotid artery proximal to the bifurcation results in migration of SMCs from the media to the intima where proliferation eventually leads to the formation of a neointima (Kumar & Lindner, 1997; Bhawan et al, 1977; Buck, 1961). Intimal thickening 18 days after ligation was inhibited 50% by ED5 (Figure 4). In contrast, neither its scrambled counterpart (Figure 4) nor the vehicle control (Figure 4) had any effect on neointima formation. These findings demonstrate the capacity of

ED5 to suppress SMC accumulation in the vascular lumen in a specific manner, and argue against inhibition as a mere consequence of a "mass effect" (Kitze et al, 1998; Tharlow et al, 1996).

Further experiments revealed the capacity of hED5 to cleave (human) EGR-1 RNA. hED5 cleaved its substrate in a dose-dependent manner over a wide range of stoichiometric ratios. hED5 also cleaved in a time-dependent manner, whereas hED5SCR, its scrambled counterpart, had no such catalytic property (data not shown).

The specific, growth-inhibitory properties of ED5 reported herein suggest that DNAzymes may be useful as therapeutic tools in the treatment of vascular disorders involving inappropriate SMC growth.

Example 2

Cleavage of human EGR-1 RNA by panel of candidate DNAzymes

To evaluate which specific DNAzymes targeting human EGR-1 (other than hED5) efficiently cleave EGR-1 RNA, we prepared *in vitro* transcribed 35S-labeled EGR-1 RNA and incubated this substrate with candidate DNAzymes for various times. The EGR-1 plasmid template (hs164) was prepared by subcloning bps 168-332 of human EGR-1 into pGEM-T-easy. A 388 nt 35S-labeled substrate was prepared by *in vitro* transcription using SP6 polymerase. Time-dependent cleavage of the substrate was tested using the following DNZzymes:

DzA: 5'-CAGGGGACAGGCTAGCTACAACGACGTTGCGGG-X-3' (SEQ ID NO: 15) ;

DzB: 5'-TGCAGGGGAGGCTAGCTACAACGAACCGTTGCG-X-3' (SEQ ID NO: 16) ;

DzC: 5'-CATCCTGGAGGCTAGCTACAACGAGAGCAGGCT-X-3' (SEQ ID NO: 17) ;

DzE: 5'-TCAGCTGCAGGCTAGCTACAACGACTCGGCCTT-X-3' (SEQ ID NO: 18) ; and

DzF: 5'-GCGGGGACAGGCTAGCTACAACGACAGCTGCAT-X-3' (SEQ ID NO: 19)

where X denotes a 3'-3-linked T.

The DNAzyme that cleaved most effectively of this group was DzA, then DzB, then DzC. In contrast, DzE was inactive.

Example 3

Inhibition of induction of EGR-1 in human SMC by DzA

To determine whether DzA could block the induction of endogenous human EGR-1, we incubated growth-quiescent human aortic smooth muscle cells with 5% fetal bovine serum and observed the production of EGR-1 protein by Western blot analysis. This band representing the EGR-1 protein was blocked by 0.5 μM DzA, delivered using FuGENE6 (Roche Molecular Biochemicals) and unaffected by DzE. The blot was then stripped and reprobed with antibodies to the transcription factor Spl. Results obtained showed that neither serum nor DzA affected induction of Sp1. A Coomassie Blue gel indicated that equal protein had been loaded.

The data demonstrate that DzA cleaves EGR-1 mRNA and blocks the induction of EGR-1 protein.

Example 4

Inhibition of human SMC proliferation by DzA

To ascertain whether proliferation of human SMCs could be inhibited by DzA, a population of SMCs was quantitated with and without exposure to DzA or DzE. SMC proliferation stimulated by 5% fetal bovine serum was significantly inhibited by 0.5 μM DzA (Figure 5). In contrast, neither DzE nor ED5SCR had any effect (Figure 5). These data demonstrate that DzA inhibits human SMC proliferation.

Example 5

Inhibition of porcine SMC proliferation by DzA

The porcine and human EGR-1 sequences are remarkably well conserved (91%). Porcine retinal SMCs were used to determine whether DzA could block the growth of porcine SMCs. Our studies indicate that DzA (0.5 μM) could inhibit the proliferation of these cells (Figure 6). In contrast, DzE had no effect (Figure 6).

Example 6

Delivery of DNAzyme into the porcine coronary artery wall

Porcine angioplasty and stenting are accepted models of human in-stent restenosis (Karas et al. 1992). The porcine coronary anatomy, dimensions and histological response to stenting are similar to the human (Muller et al. 1992). The Transport Catheter has previously been used to deliver antisense DNA targeting c-*myc* in humans (Serrys et al. 1998) and the pig (Gunn & Cumberland, 1996) via the intraluminal route. Using this catheter, FITC-labeled DNAzyme was applied to the inner wall of a porcine coronary artery, *ex vivo*, from a newly explanted pig heart. DNAzyme (1000 μg) was delivered via the catheter in 2ml MilliQ H20 containing 300μl FuGENE6 and 1mM $MgC1_2$. The FITC-labeled DNAzyme localised into the intimal cells of the vessel wall. These studies demonstrate that DNAzyme can be delivered to cells within the artery wall via an intraluminal catheter.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive. In addition, various documents are cited throughout this application. The disclosures of these documents are hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.

References

Autieri, M.V. et al (1995) Antisense oligonucleotides to the P65 subunit of NF-κB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointiima formation in rat carotid arteries. Biochem;. and Biophys. Res. Commun. 213:827-836.

Bennett, M.D. and Schwartz, S.M. (1995) Antisense Therapy for Angioplasty Restenosis. Circulation 92:1981-1993.

Bhawan, J., Joris, I., DeGerolami, U. & Majno, G. (1977) Effect of occlusion on large vessels. Am. J. Pathol. 88, 355-380.

Breaker, R.R. and Joyce, G. (1994) Chemistry and Biology 1:223-229.

Breaker, R.R. and Joyce, G. (1995) Chemistry and Biology 2:655-660.

Brogi, E., et al. (1993) Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. J. Clin. Invest. 92, 2408-2418.

Buck, R.C. (1961) Intimal thickening after ligature of arteries. Circ. Res. 9, 418-426.

Campbell, G.R. & Campbell, J.H. (1985) Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. Exp. Mol. Pathol. 42, 139-162.

Carmi, N., et al. (1996) Chemistry and Biology 3:1039-1046.

Delbridge, G.J. & Khachigian, L.M. (1997) FGF-1-induced PDGF A-chain gene expression in vascular endothelial cells involves transcriptional activation by Egr-1. Circ. Res. 81, 282-288.

Evanko, S.P., Raines, E.W., Ross, R., Gold, L.I. & Wight, T.N. (1998) Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural charcteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am. J. Pathol. 152, 533-546.

Frimerman, A. et al. (1999) Chimeric DNA-RNA Hammerhead Ribozyme to Proliferating Cell Nuclear Antigen Reduces Stent-Induced Stenosis in a Porcine Coronary Model. Circulation 99: 697-703.

Gashler, A. & Sukhatme, V. (1995) Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog. Nucl. Acid Res. 50, 191-224.

Gunn J. and Cumberland D.C. (1996) Dual balloon catheter: seminars in Interventional Cardiology 1:31-33.

Halasz, P. & Martin, P. (1984) A microcomputer-based system for semi-automatic analysis of histological sections. Proc. Royal Microscop. Soc. 19, 312.

Haseloff, J. & Gerlach, W.A. (1988) Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334, 585-591.

Holmes, D.R., et al. (1984) Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am. J. Cardiol. 53, 77C-81C.

Horodyski, J. & Powell, R.J. (1996) Effect of aprotinin on smooth muscle cell proliferation, migration, and extracellular matrix synthesis. J. Surg. Res. 66, 115-118.

Horodyski, J. & Powell, R.J. (1996) Effect of aprotinin on smooth muscle cell proliferation, migration, and extracellular matrix synthesis. J. Surg. Res. 66, 115-118.

Hughes, S.E., Crossman, D. & Hall, P.A. (1993) Expression of basic and acidic fibroblast growth factors and their receptor in normal and atherosclerotic human arteries. Cardiovasc. Res. 27, 1214-1219.

Jackson, C.L. & Schwartz, S.M. (1992) Pharmacology of smooth muscle replication. Hypertension 20, 713-736.

Karas et al. (1992) Coronary intimal proliferation after balloon injury and stenting in the sine: an animal model of restenosis. *J. Am. Coll. Cardiol.* 20, 467-474.

Kashani-Sabet, M., et al. (1992) Antisense Research and Development 2:3-15.

Khachigian, L.M. & Collins, T. (1997) Inducible expression of Egr-1-dependent genes: a paradigm of transcriptional activation in vascular endothelium. Circ. Res. 81, 457-461.

Khachigian, L.M., et al. (1997) Egr-1 is activated in endothelial cells exposed to fluid shear stress and interacts with a novel shear-stress response element in the PDGF A-chain promoter. Arterioscl. Thromb. Vasc. Biol. 17, 2280-2286.

Khachigian, L.M., Lindner, V., Williams, A.J. & Collins, T. (1996) Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 271, 1427-1431.

Khachigian, L.M., Williams, A.J. & Collins, T. (1995) Interplay of Sp1 and Egr-1 in the proximal PDGF-A promoter in cultured vascular endothelial cells. J. Biol. Chem. 270, 27679-27686.

Kim, S., et al. (1995) Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Circulation 92, 88-95.

Kitze, B., et al. (1998) Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101. Clin. Exp. Immunol. 111, 278-285.

Koizumi, M., et al. (1989) Nucleic Acids Research 17:7059-7069.

Kumar, A. & Lindner, V. (1997) Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscl. Thromb. Vasc. Biol. 17, 2238-2244.

Lemire, J.M., Covin, C.W., White, S., Giachelli, C.M. & Schwartz, S.M. (1994) Characterization of cloned aortic smooth muscle cells from young rats. Am. J. Pathol. 144, 1068-1081.

Libby, P., Schwartz, S.M., Brogi, E., Tanaka, H. & Clinton, S. (1995) A cascade model for restenosis. Circ. Res. 86 (Suppl. III), 47-52.

Majesky, M.W., Benditt, E.P. & Schwartz, S.M. (1988) Expression and developmental control of platelet-derived growth factor A-chain and B-chain/Sis genes in rat aortic smooth muscle cells. Proc. Natl. Acad. Sci. USA 85, 1524-1528.

Majesky, M.W., Giachelli, C.M., Reidy, M.A. & Schwartz, S.M. (1992) Rat carotid neointimal smooth muscle cells reexpress a developmentally regulated mRNA phenotype during repair of arterial injury. Circ. Res. 71, 759-768.

Milbrandt, J. (1987) A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science 238, 797-799

Morishita, R. et al (1993) Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides result in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA 90:8474-8478.

Muller DW et al. (1992) Experimental models of coronary artery restenosis. *J. Am. Coll. Cardiol.* 19, 418-432.

Murry, C.E., Bartosek, T., Giachelli, C.M., Alpers, C.E. & Schwartz, S.M. (1996) Platelet-derived growth factor-A mRNA expression in fetal, normal adult, and atherosclerotic human aortas. Circulation 93, 1095-1106

Otsuka, E. and Koizumi, M., Japanese Patent No. 4,235,919.

Pan, T. and Uhlenbeck, O.C. (1996) Biochemistry 31:3887-3895.

Pitsch, R.J., et al. (1996) Inhibition of smooth muscle cell proliferation and migration in vitro by antisense oligonucleotide to c-myb. J. Vasc. Surg. 23, 783-791.

Pitsch, R.J., et al. (1996) Inhibition of smooth muscle cell proliferation and migration in vitro by antisense oligonucleotide to c-myb. J. Vasc. Surg. 23, 783-791.

Raillard, S.A. and Joyce, G.F. (1996) Biochemistry 35:11693-11701.

Rafty, L.A. & Khachigian, L.M. (1998) Zinc finger transcription factors mediate high constitutive PDGF-B expression in smooth muscle cells derived from aortae of newborn rats. J. Biol. Chem. 273, 5758-5764.

Rekhter, M. & Gordon, D. (1994) Does platelet-derived growth factor-A chain stimulate proliferation of arterial mesenchymal cells in human atherosclerostic plaques? Circ. Res. 75, 410-417.

Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) Molecular cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, Plainview, N.Y.

Santoro, S.W. & Joyce, G.F. (1997) A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. USA 94, 4262-4266.

Seifert, R.A., Schwartz, S.M. & Bowen-Pope, D.F. (1984) Developmentally regulated production of platelet-derived growth factor-like molecules. Nature 311, 669-671.

Serrys PW et al. (1998) Antisense oligonucleotide against c-*myc* administered with the Transport Catheter (36-48 holes, 250 μm diameter) for the prevention of in-stent restenosis: results of randomised ITALICS trial. *Circulation* :I1909.

Silverman, E.S., Khachigian, L.M., Lindner, V., Williams, A.J. & Collins, T. (1997) Inducible PDGF A-chain transcription in vascular smooth muscle cells is mediated by Egr-1 displacement of Sp1 and Sp3. Am. J. Physiol. 42, H1415-H1426.

Stary, H.C., et al. (1995) A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Arterioscler. Thromb. Vasc. Biol. 15, 1512-1531.

Sumpio, B.E., et al. (1998) Regulation of PDGF-B by cyclic strain: lack of involvement of the shear-stress responsive element. Arterioscler. Thromb. Vasc. Biol. 18, 349-355.

Sun, L.Q., et al. (1997) Mol. Biotechnology 7:241-251.

Simons, M. et al (1992) Antisense c-*myb* oligonucleotides inhibit intimal arterial smooth muscle cell accumulation *in vivo*. Nature 359:67-70.

Symonds, R.H. (1992) Ann. Rev. Biochem. 61:641-671.

Tanizawa, S., Ueda, M., van der Loos, C.M., van der Wal, A.C. & Becker, A.E. (1996) Expression of platelet-derived growth factor B-chain and beta-receptor expression in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohisochemical study. Heart 75, 549-556

Tharlow, R.J., Hill, D.R. & Woodruff, G.N. (1996) Comparison of the autoradiographic binding distribution of [3H]-gabapentin with excitatory amino acid receptor and amino acid uptake site distributions in rat brain. Brit. J. Pharmacol. 118, 457-465.

Treisman, R. (1995) Journey to the surface of the cell: Fos regulation and the SRE. EMBO J. 14, 4905-4913.

Treisman, R. (1994) Ternary complex factor: growth factor regulated transcriptional activators. Curr. Opin. Genet. Develop. 4, 96-101.

Treisman, R. (1990) The SRE: a growth factor responsive transcriptional regulator. Sem. Cancer Biol. 1, 47-58.

Tsang, J. and Joyce, G.F. (1994) Biochemistry 33:5966-5973.

Ueda, M., et al. (1996) In situ detection of platelet-derived growth factor-A and -B chain mRNA in human coronary arteries after percutaneous transluminal coronary angioplasty. Am. J. Pathol. 149, 831-843.

Wilcox, J.N., Smith, K.M., Schwartz, S.M. & Gordon, D. (1989) Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA 86, 2839-2843.

Wilcox, J.N., Smith, K.M., Williams, L.T., Schwartz, S.M. & Gordon, D. (1988) Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J. Clin. Invest. 82, 1134-1143.

Claims:

1. A DNAzyme which specifically cleaves EGR-1 mRNA, the DNAzyme comprising

(i) a catalytic domain which cleaves mRNA at a purine:pyrimidine cleavage site;

(ii) a first binding domain contiguous with the 5' end of the catalytic domain; and

(iii) a second binding domain contiguous with the 3' end of the catalytic domain,

wherein the binding domains are sufficiently complementary to the two regions immediately flanking a purine:pyrimidine cleavage site within the region of EGR-1 mRNA corresponding to nucleotides 168 to 332 as shown in SEQ ID NO:1, such that the DNAzyme cleaves the EGR-1 mRNA.

2. A DNAzyme as claimed in claim 1 wherein each binding domain is nine or more nucleotides in length.

3. A DNAzyme as claimed in claim 1 or claim 2 in which the catalytic domain has the nucleotide sequence GGCTAGCTACAACGA (SEQ ID NO: 2).

4. A DNAzyme as claimed in any one of claims 1 to 3 in which the cleavage site is selected from the group consisting of

(i) the GU site corresponding to nucleotides 198-199;
(ii) the GU site corresponding to nucleotides 200-201;
(iii) the GU site corresponding to nucleotides 264-265;
(iv) the AU site corresponding to nucleotides 271-272;
(v) the AU site corresponding to nucleotides 301-302;
(vi) the GU site corresponding to nucleotides 303-304; and
(vii) the AU site corresponding to nucleotides 316-317.

5. A DNAzyme as claimed in claim 4 in which the cleavage site is the AU site corresponding to nucleotides 271-272.

6. A DNAzyme as claimed in claim 1 which has a sequence selected from the group consisting of:

(i) 5'-caggggacaGGCTAGCTACAACGAcgttgcggg (SEQ ID NO: 3);
(ii) 5'-tgcaggggaGGCTAGCTACAACGAaccgttgcg (SEQ ID NO: 4);
(iii) 5'-catcctggaGGCTAGCTACAACGAgagcaggct (SEQ ID NO: 5);
(iv) 5'-ccgcggccaGGCTAGCTACAACGAcctggacga (SEQ ID NO: 6);
(v) 5'-ccgctgccaGGCTAGCTACAACGAcccggacgt (SEQ ID NO: 7);
(vi) 5'-gcggggacaGGCTAGCTACAACGAcagctgcat (SEQ ID NO: 8);
(vii) 5'-cagcggggaGGCTAGCTACAACGAatcagctgc (SEQ ID NO: 9); and
(viii) 5'-ggtcagagaGGCTAGCTACAACGActgcagcgg (SEQ ID NO: 10).

7. A DNAzyme as claimed in claim 6 which has the sequence: 5'-ccgcggccaGGCTAGCTACAACGAcctggacga (SEQ ID NO: 6).

8. A DNAzyme as claimed in any one of claims 1 to 7, wherein the 3'-end nucleotide residue is inverted in the binding domain contiguous with the 3' end of the catalytic domain.

9. A pharmaceutical composition comprising a DNAzyme according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier.

10. A method of inhibiting EGR-1 activity in cells which comprises exposing the cells to a DNAzyme according to any one of claims 1 to 8.

11. A method of inhibiting proliferation or migration of cells in a subject which comprises administering to the subject a prophylactically effective dose of the pharmaceutical composition according to claim 9.

12. A method of treating a condition associated with cell proliferation or migration in a subject which comprises administering to the subject a therapeutically effective dose of the pharmaceutical composition according to claim 9.

13. A method as claimed in any one of claims 10 to 12 wherein the cells are vascular cells.

14. A method as claimed in any one of claims 10 to 12 wherein the cells are cells involved in neoplasia.

15. A method as claimed in claim 12 wherein the condition associated with cell proliferation or migration is selected from the group consisting of post-angioplasty restenosis, vein graft failure, hypertension, transplant coronary disease and complications associated with atherosclerosis or peripheral vascular disease.

16. An angioplastic stent for inhibiting the onset of restenosis, which comprises an angioplastic stent operably coated with a prophylactically effective dose of a DNAzyme according to any one of claims 1 to 8.

17. A method for inhibiting the onset of restenosis in a subject undergoing angioplasty, which comprises topically administering a prophylactically effective dose of a pharmaceutical composition according to claim 9 to the subject at around the time of the angioplasty.

18. A method according to claim 17 in which the pharmaceutical composition is administered by catheter.

19. A method for inhibiting the onset of restenosis in a subject undergoing angioplasty, which comprises topically administering a stent according to claim 15 to the subject at around the time of the angioplasty.

ABSTRACT

The present invention relates to DNAzymes which are targeted against mRNA molecules encoding EGR-1 (also known as Egr-1 and NGFI-A). The present invention also relates to compositions including these DNAzymes and to methods of treatment involving administration of the DNAzymes.



ED5



ED5SCR

Figure 1


FBS
SFM
ED5
ED5SCR
NGFI-A
β-Actin
NGFI-A / β-Actin
0.8
0.6
0.4
0.2
0.0
SFM
ED5
ED5SCR
FBS

Figure 2



Figure 3A



Figure 3B


80000
60000
40000
20000
0
Total Cell Count
SFM
ED5
ED5SCR
FBS

Figure 3C


1.0
0.8
0.6
0.4
0.2
0.0
Neointima / Media
*
Lig
Lig+Veh
Lig+Veh+ED5
Lig+Veh+ED5SCR

Figure 4



Figure 5



Figure 6

DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled "**CATALYTIC MOLECULES**," the specification of which was filed as International Application No. PCT/AU00/00011 on January 11, 2000 and was transmitted to the U.S. Receiving Office on July 11, 2001 together with a Preliminary Amendment dated July 11, 2001, and which was assigned Application Serial No. 09/889,075. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

(Application Serial Number)	(Country)	(Day/Month/Year Filed)	Priority Claimed ☒ Yes	☐ No
PP8103	Australia	11/January/1999		

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

(Application Serial Number)	(Day/Month/Year Filed)
NONE	

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

(Application Serial Number)	(Day/Month/Year Filed)	(Status-Patented, Pending or Abandoned)
NONE		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: I hereby appoint as my attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

24

John B. Lungmus (18,566)	Richard H Anderson (26,526)	Martin J. Hirsch (32,237)	James A. Flight (37,622)
Allen H. Gerstein (22,218)	Patrick D Ertel (26,877)	James J. Napoli (32,361)	Roger A Heppermann (37,641)
Nate F. Scarpelli (22,320)	Richard B Hoffman (26,910)	Richard M La Barge (32,254)	David A Gass (38,153)
Michael F. Borun (25,447)	James P Zeller (28,491)	Douglass C Hochstetler (33,710)	Gregory C Mayer (38,238)
Trevor B. Joike (25,542)	Kevin D Hogg (31,839)	Robert M. Gerstein (34,824)	Michael R Weiner (38,359)
Carl E. Moore, Jr. (26,487)	Jeffrey S Sharp (31,879)	Anthony G. Sitko (36,278)	William K. Merkel (40,725)

Send correspondence to: David A. Gass

FIRM NAME	PHONE NO.	STREET	CITY & STATE	ZIP CODE
Marshall, Gerstein & Borun	312-474-6300	6300 Sears Tower 233 South Wacker Drive	Chicago, Illinois	60606-6402

1.00

Full Name of First or Sole Inventor David G. Atkins	Citizenship AU
Residence Address - Street 45W 60th St., Apt 17A	Post Office Address - Street 45W 60th St., Apt 17A
City (Zip) New York 10023 NY	City (Zip) New York 10023
State or Country New York	State or Country New York
Date ☒ 1 NOVEMBER 2001	Signature ☒

2.00

Second Joint Inventor, if any Andrew R. Baker	Citizenship AU
Residence Address - Street 3 Adelong Place	Post Office Address - Street 3 Adelong Place
City (Zip) Wahroonga 2076 WLS	City (Zip) Wahroonga 2076
State or Country New South Wales	State or Country New South Wales
Date ☒ 15 NOVEMBER 2001	Signature ☒

3.00

Third Joint Inventor, if any Levon Michael Khachigian	Citizenship AU
Residence Address - Street 5 Ratcliffe Street	Post Office Address - Street 5 Ratcliffe Street
City (Zip) Ryde 2112	City (Zip) Ryde 2112
State or Country New South Wales WLS	State or Country New South Wales
Date ☒ 9 November 2001	Signature ☒ LevonKhachigian

APPLICABLE RULES AND STATUTES

37 CFR 1.56. DUTY OF DISCLOSURE - INFORMATION MATERIAL TO PATENTABILITY (Applicable Portion)

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

(1) prior art cited in search reports of a foreign patent office in a counterpart application, and
(2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentability defines, to make sure that any material information contained therein is disclosed to the Office.

Information relating to the following factual situations enumerated in 35 USC 102 and 103 may be considered material under 37 CFR 1.56(a).

35 U.S.C. 102. CONDITIONS FOR PATENTABILITY: NOVELTY AND LOSS OF RIGHT TO PATENT

A person shall be entitled to a patent unless --

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or

(c) he has abandoned the invention, or

(d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States, or

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraph (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent, or

(f) he did not himself invent the subject matter sought to be patented, or

(g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

35 U.S.C. 103. CONDITIONS FOR PATENTABILITY; NON-OBVIOUS SUBJECT MATTER (Applicable Portion)

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

35 U.S.C. 112. SPECIFICATION (Applicable Portion)

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

SEQUENCE LISTING

<110> Johnson & Johnson Pty Ltd
Unisearch Limited

<120> Catalytic molecules

<150> PP 8103
<151> 1999-01-11

<160> 20

<170> PatentIn Ver. 2.1

<210> 1
<211> 3132
<212> DNA
<213> Homo sapiens

<400> 1
ccgcagaact tggggagccg ccgccgccat ccgccgccgc agccagcttc cgccgccgca 60
ggaccggccc ctgccccagc ctccgcagcc gcggcgcgtc cacgcccgcc cgcgcccagg 120
gcgagtcggg gtcgccgcct gcacgcttct cagtgttccc cgcgccccgc atgtaacccg 180
gccaggcccc cgcaacggtg tcccctgcag ctccagcccc gggctgcacc ccccgccccc 240
gacaccagct ctccagcctg ctcgtccagg atggccgcgg ccaaggccga gatgcagctg 300
atgtccccgc tgcagatctc tgacccgttc ggatcctttc ctcactcgcc caccatggac 360
aactacccta agctggagga gatgatgctg ctgagcaacg gggctcccca gttcctcggc 420
gccgccgggg ccccagaggg cagcggcagc aacagcagca gcagcagcag cgggggcggt 480
ggaggcggcg ggggcggcag caacagcagc agcagcagca gcaccttcaa ccctcaggcg 540
gacacgggcg agcagcccta cgagcacctg accgcagagt cttttcctga catctctctg 600
aacaacgaga aggtgctggt ggagaccagt taccccagcc aaaccactcg actgcccccc 660
atcacctata ctggccgctt ttccctggag cctgcaccca acagtggcaa caccttgtgg 720
cccgagcccc tcttcagctt ggtcagtggc ctagtgagca tgaccaaccc accggcctcc 780
tcgtcctcag caccatctcc agcggcctcc tccgcctccg cctcccagag cccaccctg 840
agctgcgcag tgccatccaa cgacagcagt cccatttact cagcggcacc caccttcccc 900
acgccgaaca ctgacatttt ccctgagcca caaagccagg ccttcccggg ctcggcaggg 960
acagcgctcc agtacccgcc tcctgcctac cctgccgcca agggtggctt ccaggttccc 1020
atgatccccg actacctgtt tccacagcag caggggatc tgggcctggg caccccagac 1080
cagaagccct tccagggcct ggagagccgc acccagcagc cttcgctaac ccctctgtct 1140
actattaagg cctttgccac tcagtcgggc tcccaggacc tgaaggccct caataccagc 1200
taccagtccc agctcatcaa acccagccgc atgcgcaagt atcccaaccg gcccagcaag 1260
acgccccccc acgaacgccc ttacgcttgc ccagtggagt cctgtgatcg ccgcttctcc 1320
cgctccgacg agctcacccg ccacatccgc atccacacag gccagaagcc cttccagtgc 1380
cgcatctgca tgcgcaactt cagccgcagc gaccacctca ccacccacat ccgcacccac 1440
acaggcgaaa agcccttcgc ctgcgacatc tgtggaagaa agtttgccag gagcgatgaa 1500
cgcaagaggc ataccaagat ccacttgcgg cagaaggaca agaaagcaga caaaagtgtt 1560
gtggcctctt cggccacctc ctctctctct tcctacccgt ccccggttgc tacctcttac 1620
ccgtccccgg ttactacctc ttatccatcc ccggccacca cctcataccc atcccctgtg 1680
cccacctcct tctcctctcc cggctcctcg acctacccat cccctgtgca cagtggcttc 1740
ccctccccgt cggtggccac cacgtactcc tctgttcccc ctgctttccc ggcccaggtc 1800
agcagcttcc cttcctcagc tgtcaccaac tccttcagcg cctccacagg gctttcggac 1860
atgacagcaa ccttttctcc caggacaatt gaaatttgct aaagggaaag gggaaagaaa 1920
gggaaaaggg agaaaaagaa acacaagaga cttaaaggac aggaggagga gatggccata 1980
ggagaggagg gttcctctta ggtcagatgg aggttctcag agccaagtcc tccctctcta 2040
ctggagtgga aggtctattg gccaacaatc ctttctgccc acttcccctt ccccaattac 2100
tattcccttt gacttcagct gcctgaaaca gccatgtcca agttcttcac ctctatccaa 2160
agaacttgat ttgcatggat tttggataaa tcatttcagt atcatctcca tcatatgcct 2220
gacccttgc tcccttcaat gctagaaaat cgagttggca aaatggggtt tgggcccctc 2280
agagccctgc cctgcaccct tgtacagtgt ctgtgccatg gatttcgttt ttcttggggt 2340
actcttgatg tgaagataat ttgcatattc tattgtatta tttggagtta ggtcctcact 2400

tgggggaaaa aaaaaaaaaa aagccaagca aaccaatggt gatcctctat tttgtgatga 2460
tgctgtgaca ataagtttga acctttttt ttgaaacagc agtcccagta ttctcagagc 2520
atgtgtcaga gtgttgttcc gttaaccttt ttgtaaatac tgcttgaccg tactctcaca 2580
tgtggcaaaa tatggtttgg ttttttcttt ttttttttga aagtgttttt tcttcgtcct 2640
tttggtttaa aaagtttcac gtcttggtgc cttttgtgtg atgccccttg ctgatggctt 2700
gacatgtgca attgtgaggg acatgctcac ctctagcctt aaggggggca gggagtgatg 2760
atttgggggа ggctttggga gcaaaataag gaagagggct gagctgagct tcggttctcc 2820
agaatgtaag aaaacaaaat ctaaaacaaa atctgaactc tcaaaagtct attttttaa 2880
ctgaaaatgt aaatttataa atatattcag gagttggaat gttgtagtta cctactgagt 2940
aggcggcgat ttttgtatgt tatgaacatg cagttcatta ttttgtggtt ctattttact 3000
ttgtacttgt gtttgcttaa acaaagtgac tgtttggctt ataaacacat tgaatgcgct 3060
ttattgccca tgggatatgt ggtgtatatc cttccaaaaa attaaaacga aaataaagta 3120
gctgcgattg gg 3132

<210> 2
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Catalytic domain of DNAzyme

<400> 2
ggctagctac aacga 15

<210> 3
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 3
caggggacag gctagctaca acgacgttgc ggg 33

<210> 4
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 4
tgcaggggag gctagctaca acgaaccgtt gcg 33

<210> 5
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 5
catcctggag gctagctaca acgagagcag gct 33

<210> 6
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 6
ccgcggccag gctagctaca acgacctgga cga 33

<210> 7
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 7
ccgctgccag gctagctaca acgacccgga cgt 33

<210> 8
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 8
gcggggacag gctagctaca acgacagctg cat 33

<210> 9
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 9
cagcggggag gctagctaca acgaatcagc tgc 33

<210> 10
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 10
ggtcagagag gctagctaca acgactgcag cgg 33

<210> 11
<211> 3068
<212> DNA
<213> Mus musculus

<400> 11
ggggagccgc cgccgcgatt cgccgccgcc gccagcttcc gccgccgcaa gatcggcccc 60
tgccccagcc tccgcggcag ccctgcgtcc accacgggcc gcggctaccg ccagcctggg 120
ggcccacctа cactccccgc agtgtgcccc tgcaccccgc atgtaacccg gccaaccccc 180
ggcgagtgtg ccctcagtag cttcggcccc gggctgcgcc caccacccaa catcagttct 240
ccagctcgct ggtccgggat ggcagcggcc aaggccgaga tgcaattgat gtctccgctg 300
cagatctctg acccgttcgg ctcctttcct cactcaccca ccatggacaa ctaccccaaa 360
ctggaggaga tgatgctgct gagcaacggg gctccccagt tcctcggtgc tgccggaacc 420
ccagagggca gcggcggtaa tagcagcagc agcaccagca gcgggggcgg tggtgggggc 480
ggcagcaaca gcggcagcag cgccttcaat cctcaagggg agccgagcga acaaccctat 540
gagcacctga ccacagagtc cttttctgac atcgctctga ataatgagaa ggcgatggtg 600
gagacgagtt atcccagcca aacgactcgg ttgcctccca tcacctatac tggccgcttc 660
tccctggagc ccgcacccaa cagtggcaac actttgtggc ctgaacccct tttcagccta 720
gtcagtggcc tcgtgagcat gaccaatcct ccgacctctt catcctcggc gccttctcca 780
gctgcttcat cgtcttcctc tgcctcccag agcccgcccc tgagctgtgc cgtgccgtcc 840
aacgacagca gtcccatcta ctcggctgcg cccacctttc ctactcccaa cactgacatt 900
tttcctgagc cccaaagcca ggcctttcct ggctcggcag gcacagcctt gcagtacccg 960
cctcctgcct accctgccac caaaggtggt ttccaggttc ccatgatccc tgactatctg 1020
tttccacaac aacagggaga cctgagcctg ggcaccccag accagaagcc cttccagggt 1080
ctggagaacc gtacccagca gccttcgctc actccactat ccactattaa agccttcgcc 1140
actcagtcgg gctcccagga cttaaaggct cttaatacca cctaccaatc ccagctcatc 1200
aaacccagcc gcatgcgcaa gtaccccaac cggcccagca agacaccccc ccatgaacgc 1260
ccatatgctt gccctgtcga gtcctgcgat cgccgctttt ctcgctcgga tgagcttacc 1320
cgccatatcc gcatccacac aggccagaag cccttccagt gtcgaatctg catgcgtaac 1380
ttcagtcgta gtgaccacct taccacccac atccgcaccc acacaggcga gaagcctttt 1440
gcctgtgaca tttgtgggag gaagtttgcc aggagtgatg aacgcaagag gcataccaaa 1500
atccatttaa gacagaagga caagaaagca gacaaaagtg tggtggcctc cccggctgcc 1560
tcttcactct cttcttaccc atccccagtg gctacctcct acccatcccc tgccaccacc 1620
tcattcccat cccctgtgcc cacttcctac tcctctcctg gctcctccac ctacccatct 1680
cctgcgcaca gtggcttccc gtcgccgtca gtggccacca cctttgcctc cgttccacct 1740
gctttcccca cccaggtcag cagcttcccg tctgcgggcg tcagcagctc cttcagcacc 1800
tcaactggtc tttcagacat gacagcgacc ttttctccca ggacaattga aatttgctaa 1860
agggaataaa agaaagcaaa gggagaggca ggaaagacat aaaagcacag gagggaagag 1920
atggccgcaa gaggggccac ctcttaggtc agatggaaga tctcagagcc aagtccttct 1980
actcacgagt agaaggaccg ttggccaaca gccctttcac ttaccatccc tgcctccccc 2040
gtcctgttcc ctttgacttc agctgcctga aacagccatg tccaagttct tcacctctat 2100
ccaaaggact tgatttgcat ggtattggat aaatcatttc agtatcctct ccatcacatg 2160
cctggccctt gctccttca gcgctagacc atcaagttgg cataaagaaa aaaaaatggg 2220
tttgggccct cagaaccctg ccctgcatct ttgtacagca tctgtgccat ggattttgtt 2280
ttccttgggg tattcttgat gtgaagataa tttgcatact ctattgtatt atttggagtt 2340
aaatcctcac tttgggggag gggggagcaa agccaagcaa accaatgatg atcctctatt 2400
ttgtgatgac tctgctgtga cattaggttt gaagcatttt ttttttcaag cagcagtcct 2460
aggtattaac tggagcatgt gtcagagtgt tgttccgtta attttgtaaa tactggctcg 2520
actgtaactc tcacatgtga caaagtatgg tttgtttggt tgggttttgt ttttgagaat 2580
tttttgccc gtccctttgg tttcaaaagt ttcacgtctt ggtgcctttt gtgtgacacg 2640
ccttccgatg gcttgacatg cgcagatgtg agggacacgc tcaccttagc cttaaggggg 2700
taggagtgat gtgttgggggg aggcttgaga gcaaaaacga ggaagagggc tgagctgagc 2760
tttcggtctc cagaatgtaa gaagaaaaaa tttaaacaaa aatctgaact ctcaaaagtc 2820
tatttttcta aactgaaaat gtaaatttat acatctattc aggagttgga gtgttgtggt 2880
tacctactga gtaggctgca gtttttgtat gttatgaaca tgaagttcat tattttgtgg 2940
ttttatttta ctttgtactt gtgtttgctt aaacaaagta acctgtttgg cttataaaca 3000

cattgaatgc gctctattgc ccatgggata tgtggtgtgt atccttcaga aaaattaaaa 3060
ggaaaaat 3068

<210> 12
<211> 4321
<212> DNA
<213> Rattus rattus

<400> 12
ccgcggagcc tcagctctac gcgcctggcg ccctccctac gcgggcgtcc ccgactcccg 60
cgcgcgttca ggctccgggt tgggaaccaa ggaggggggag ggtgggtgcg ccgacccgga 120
aacaccatat aaggagcagg aaggatcccc cgccggaaca gaccttattt gggcagcgcc 180
ttatatggag tggcccaata tggccctgcc gcttccggct ctgggaggag gggcgaacgg 240
gggttggggc gggggcaagc tgggaactcc aggagcctag cccgggaggc cactgccgct 300
gttccaatac taggctttcc aggagcctga gcgctcaggg tgccggagcc ggtcgcaggg 360
tggaagcgcc caccgctctt ggatgggagg tcttcacgtc actccgggtc ctcccggtcg 420
gtccttccat attagggctt cctgcttccc atatatggcc atgtacgtca cggcggaggc 480
gggcccgtgc tgtttcagac ccttgaaata gaggccgatt cggggagtcg cgagagatcc 540
cagcgcgcag aacttgggga gccgccgccg cgattcgccg ccgccgccag cttccgccgc 600
cgcaagatcg gcccctgccc cagcctccgc ggcagccctg cgtccaccac gggccgcggc 660
caccgccagc ctgggggccc acctacactc cccgcagtgt gcccctgcac cccgcatgta 720
acccggccaa catccggcga gtgtgccctc agtagcttcg gccccgggct gcgcccacca 780
cccaacatca gctctccagc tcgcacgtcc gggatggcag cggccaaggc cgagatgcaa 840
ttgatgtctc cgctgcagat ctctgacccg ttcggctcct ttcctcactc acccaccatg 900
gacaactacc ccaaactgga ggagatgatg ctgctgagca acggggctcc ccagttcctc 960
ggtgctgccg gaaccccaga gggcagcggc ggcaataaca gcagcagcag cagcagcagc 1020
agcagcgggg gcggtggtgg gggcggcagc aacagcggca gcagcgcttt caatcctcaa 1080
ggggagccga gcgaacaacc ctacgagcac ctgaccacag gtaagcggtg gtctgcgccg 1140
aggctgaatc ccccttcgtg actaccctaa cgtccagtcc tttgcagcac ggacctgcat 1200
ctagatctta gggacgggat tgggatttcc ctctattcca cacagctcca gggacttgtg 1260
ttagagggat gtctggggac cccccaaccc tccatccttg cgggtgcgcg gagggcagac 1320
cgtttgtttt ggatggagaa ctcaagttgc gtgggtggct ggagtggggg agggtttgtt 1380
ttgatgagca gggttgcccc ctccccccgcg cgcgttgtcg cgagccttgt ttgcagcttg 1440
ttcccaagga agggctgaaa tctgtcacca gggatgtccc gccgcccagg gtaggggcgc 1500
gcattagctg tggccactag ggtgctggcg ggattccctc accccggacg cctgctgcgg 1560
agcgctctca gagctgcagt agaggggat tctctgtttg cgtcagctgt cgaaatggct 1620
ctgccactgg agcaggtcca ggaacattgc aatctgctgc tatcaattat taaccacatc 1680
gagagtcagt ggtagccggg cgacctcttg cctggccgct tcggctctca tcgtccagtg 1740
attgctctcc agtaaccagg cctctctgtt ctctttcctg ccagagtcct tttctgacat 1800
cgctctgaat aacgagaagg cgctggtgga gacaagttat cccagccaaa ctacccggtt 1860
gcctcccatc acctatactg gccgcttctc cctggagcct gcacccaaca gtggcaacac 1920
tttgtggcct gaaccccttt tcagcctagt cagtggcctt gtgagcatga ccaaccctcc 1980
aacctcttca tcctcagcgc cttctccagc tgcttcatcg tcttcctctg cctcccagag 2040
cccacccctg agctgtgccg tgccgtccaa cgacagcagt cccatttact cagctgcacc 2100
caccttttct actcccaaca ctgacatttt tcctgagccc caaagccagg cctttcctgg 2160
ctctgcaggc acagcctttgc agtacccgcc tcctgcctac cctgccacca agggtggttt 2220
ccaggttccc atgatccctg actatctgtt tccacaacaa cagggagacc tgagcctggg 2280
cacccagac cagaagccct tccagggtct ggagaaccgt acccagcagc cttcgctcac 2340
tccactatcc actatcaaag ccttcgccac tcagtcgggc tcccaggact taaaggctct 2400
taataacacc taccagtccc aactcatcaa acccagccgc atgcgcaagt accccaaccg 2460
gcccagcaag acacccccccc atgaacgccc gtatgcttgc cctgttgagt cctgcgatcg 2520
ccgcttttct cgctcggatg agcttacacg ccacatccgc atccatacag gccagaagcc 2580
cttccagtgt cgaatctgca tgcgtaattt cagtcgtagt gaccacctta ccacccacat 2640
ccgcacccac acaggcgaga agccttttgc ctgtgacatt tgtgggagaa agtttgccag 2700
gagtgatgaa cgcaagaggc ataccaaaat ccacttaaga cagaaggaca agaaagcaga 2760
caaaagtgtc gtggcctcct cagctgcctc ttccctctct tcctacccat ccccagtggc 2820
tacctcctac ccatcccccg ccaccacctc atttccatcc ccagtgccca cctcttactc 2880
ctctccgggc tcctctacct acccgtctcc tgcacacagt ggcttcccat cgccctcggt 2940
ggccaccacc tatgcctccg tcccacctgc tttccctgcc caggtcagca ccttccagtc 3000

tgcaggggtc agcaactcct tcagcacctc aacgggtctt tcagacatga cagcaacctt 3060
ttctcctagg acaattgaaa tttgctaaag ggaatgaaag agagcaaagg gaggggagcg 3120
cgagagacaa taaaggacag gagggaagaa atggcccgca agaggggctg cctcttaggt 3180
cagatggaag atctcagagc caagtccttc tagtcagtag aaggcccgtt ggccaccagc 3240
cctttcactt agcgtccctg ccctccccag tcccggtcct tttgacttca gctgcctgaa 3300
acagccacgt ccaagttctt cacctctatc caaaggactt gatttgcatg gtattggata 3360
aaccatttca gcatcatctc caccacatgc ctggcccttg ctcccttcag cactagaaca 3420
tcaagttggc tgaaaaaaaa aatgggtctg ggccctcaga accctgccct gtatctttgt 3480
acagcatctg tgccatggat tttgttttcc ttggggtatt cttgatgtga agataatttg 3540
catactctat tgtactattt ggagttaaat tctcactttg ggggaggggg agcaaagcca 3600
agcaaaccaa tggtgatcct ctattttgtg atgatcctgc tgtgacatta ggtttgaaac 3660
ttttttttt ttttgaagca gcagtcctag gtattaactg gagcatgtgt cagagtgttg 3720
ttccgttaat tttgtaaata ctgctcgact gtaactctca catgtgacaa aatacggttt 3780
gtttggttgg gttttttgtt gtttttgaaa aaaaaatttt ttttttgccc gtccctttgg 3840
tttcaaaagt ttcacgtctt ggtgcctttg tgtgacacac cttgccgatg gctggacatg 3900
tgcaatcgtg aggggacacg ctcacctcta gccttaaggg ggtaggagtg atgtttcagg 3960
ggaggcttta gagcacgatg aggaagaggg ctgagctgag ctttggttct ccagaatgta 4020
agaagaaaaa tttaaaacaa aaatctgaac tctcaaaagt ctatttttt aactgaaaat 4080
gtagatttat ccatgttcgg gagttggaat gctgcggtta cctactgagt aggcggtgac 4140
ttttgtatgc tatgaacatg aagttcatta ttttgtggtt ttattttact tcgtacttgt 4200
gtttgcttaa acaaagtgac ttgtttggct tataaacaca ttgaatgcgc tttactgccc 4260
atgggatatg tggtgtgtat ccttcagaaa aattaaaagg aaaataaaga aactaactgg 4320
t 4321

<210> 13
<211> 19
<212> RNA
<213> Rattus rattus

<400> 13
acguccggga uggcagcgg 19

<210> 14
<211> 19
<212> RNA
<213> Homo sapiens

<400> 14
ucguccagga uggccgcgg 19

<210> 15
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (33)..(34)
<223> 3'-3-linked T

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 15
caggggacag gctagctaca acgacgttgc gggt 34

<210> 16
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (33)..(34)
<223> 3'-3-linked T

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 16
tgcaggggag gctagctaca acgaaccgtt gcgt 34

<210> 17
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (33)..(34)
<223> 3'-3-linked T

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 17
catcctggag gctagctaca acgagagcag gctt 34

<210> 18
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (33)..(34)
<223> 3'-3-linked T

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 18
tcagctgcag gctagctaca acgactcggc cttt 34

<210> 19
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (33)..(34)
<223> 3'-3-linked T

<220>
<223> Description of Artificial Sequence: DNAzyme

<400> 19
gcggggacag gctagctaca acgacagctg catt 34

<210> 20
<211> 15
<212> DNA
<213> Rattus rattus

<400> 20
cttggccgct gccat 15

United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☑ Page(s)_____ of Express Mail _____ were not present for scanning.
(Document title)

☐ Page(s)_____ of _____ were not present for scanning.
(Document title)

▫ ***Scanned copy is best available.***